GRFS 20-F DEF-14A Report Dec. 31, 2010 | Alphaminr
ALPHAMINR

GRFS 20-F Report ended Dec. 31, 2010

Balance Sheet
Cash Flow
Income Statement
20-F 1 y90639e20vf.htm FORM 20-F e20vf
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 20-F
o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2010
OR
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______________ to _____________
o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report .............
Commission file number:
GRIFOLS, S.A.
(Exact name of Registrant as specified in its charter and translation of Registrant’s name into English)
Spain
(Jurisdiction of incorporation or organization)
Avinguda de la Generalitat, 152-158
Parc de Negocis Can Sant Joan
Sant Cugat del Valles 08174
Barcelona, Spain
(Address of principal executive offices)
Securities registered or to be registered pursuant to Section 12(b) of the Act:
Title of each class Name of each exchange on which registered
American Depositary Shares evidenced by American Depositary Receipts, each American Depositary Share representing one-half of one non-voting (Class B) ordinary share of Grifols, S.A.
Securities registered or to be registered pursuant to Section 12(g) of the Act: None
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
Yes o No þ
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Yes o No þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes o No þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o Accelerated filer o Non-accelerated filer þ
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP o
International Financial Reporting Standards as issued by the International Accounting Standards Board þ Other o
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow:
Item 17 o Item 18 o
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes o No þ

EXPLANATORY NOTE
On January 14, 2011, the Securities and Exchange Commission (the “SEC”) declared effective the Registration Statement on Form F-4 (Commission File No. 333-168701) (“Form F-4 Registration Statement”), of Grifols, S.A., a company (sociedad anónima) organized under the laws of Spain (“Grifols”), relating to Grifols’ acquisition of Talecris Biotherapeutics Holdings Corp.
Rule 15d-2 (“Rule 15d-2”) under the Securities Exchange Act of 1934, as amended, provides generally that if a company’s registration statement under the Securities Act of 1933, as amended, does not contain certified financial statements for the company’s last full fiscal year preceding the year in which the registration statement becomes effective (or for the life of the company if less than a full fiscal year), then the company must, within the later of 90 days after the effective date of the registration statement or six months following the end of the registrant’s latest full fiscal year, file a special financial report furnishing certified financial statements for the last full fiscal year or other period, as the case may be, meeting the requirements of the form appropriate for annual reports of that company. Rule 15d-2 further provides that the special financial report is to be filed under cover of the facing sheet of the form appropriate for annual reports of the company.
The Form F-4 Registration Statement did not contain the certified financial statements of Grifols for the year ended December 31, 2010; therefore, as required by Rule 15d-2, Grifols is hereby filing the certified financial statements of Grifols with the SEC under cover of the facing page of an annual report on Form 20-F.

Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders of
Grifols, S.A.
Barcelona, Spain
We have audited the accompanying consolidated balance sheets of Grifols, S.A. and subsidiaries (“the Company”) as of December 31, 2010 and 2009, and the related consolidated income statements, consolidated statements of comprehensive income, statements of changes in consolidated equity and consolidated statements of cash flows for each of the years in the three-year period ended December 31, 2010. These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Grifols, S.A. and subsidiaries as of December 31, 2010 and 2009, and the results of their operations and their cash flows for each of the years in the three-year period ended December 31, 2010, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
/s/ KPMG Auditores, S.L.

Barcelona, Spain, March 30, 2011

GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Balance Sheets
at 31 December 2010 and 2009
Assets 31/12/10 31/12/09
(Expressed in thousands of Euros)
Non-current assets
Intangible assets
Goodwill (note 7)
189,448 174,000
Other intangible assets (note 8)
78,299 69,385
Total intangible assets
267,747 243,385
Property, plant and equipment (note 9)
434,131 371,705
Investments in equity accounted investees (note 10)
598 383
Non-current financial assets (note 11)
7,535 3,731
Deferred tax assets (note 29)
34,889 33,395
Total non-current assets
744,900 652,599
Current assets
Inventories (note 12)
527,865 484,462
Trade and other receivables
Trade receivables
224,355 207,840
Other receivables
44,032 39,540
Current income tax assets
14,607 7,802
Trade and other receivables (note 13)
282,994 255,182
Other current financial assets (note 14)
12,946 8,217
Other current assets (note 15)
80,628 7,345
Cash and cash equivalents (note 16)
239,649 249,372
Total current assets
1,144,082 1,004,578
Total assets
1,888,982 1,657,177
The accompanying notes form an integral part of the consolidated financial statements.

1

GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Balance Sheets
at 31 December 2010 and 2009
Equity and liabilities 31/12/10 31/12/09
(Expressed in thousands of Euros)
Equity
Share capital
106,532 106,532
Share premium
121,802 121,802
Reserves
403,604 314,903
Own shares
(1,927 ) (677 )
Interim dividend
0 (31,960 )
Profit for the year attributable to the Parent
115,513 147,972
Total equity
745,524 658,572
Cash flow hedges
(1,751 ) (1,948 )
Translation differences
(50,733 ) (90,253 )
Accumulated other comprehensive income
(52,484 ) (92,201 )
Equity attributable to the Parent (note 17)
693,040 566,371
Non-controlling interests (note 19)
14,350 12,157
Total equity
707,390 578,528
Liabilities
Non-current liabilities
Grants (note 20)
2,088 2,311
Provisions (note 21)
1,378 1,232
Non-current financial liabilities
Loans and borrowings, bonds and other marketable securities
665,385 703,186
Other financial liabilities
10,474 12,552
Total non-current financial liabilities (note 22)
675,859 715,738
Deferred tax liabilities (note 29)
79,141 60,325
Total non-current liabilities
758,466 779,606
Current liabilities
Provisions (note 21)
4,365 4,702
Current financial liabilities
Loans and borrowings, bonds and other marketable securities
191,635 113,991
Other financial liabilities
18,236 12,230
Total current financial liabilities (note 22)
209,871 126,221
Debts with associates (note 33)
1,162 0
Trade and other payables
Suppliers
160,678 120,909
Other payables
11,928 17,832
Current income tax liabilities
4,172 3,258
Total trade and other payables (note 23)
176,778 141,999
Other current liabilities (note 24)
30,950 26,121
Total current liabilities
423,126 299,043
Total liabilities
1,181,592 1,078,649
Total equity and liabilities
1,888,982 1,657,177
The accompanying notes form an integral part of the consolidated financial statements.

2

GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Income Statements
for the years ended 31 December 2010, 2009 and 2008
31/12/10 31/12/09 31/12/08
(Expressed in thousands of Euros)
Revenues (note 25)
990,730 913,186 814,311
Changes in inventories of finished goods and work in progress (note 12)
45,749 73,093 31,058
Self-constructed non-current assets (notes 8 and 9)
33,513 41,142 25,794
Supplies (note 12)
(306,859 ) (286,274 ) (206,738 )
Other operating income (note 27)
1,196 1,443 1,289
Personnel expenses (note 26)
(289,008 ) (273,168 ) (238,159 )
Other operating expenses (note 27)
(220,218 ) (203,381 ) (192,288 )
Amortisation and depreciation (notes 8 and 9)
(45,776 ) (39,554 ) (33,256 )
Non-financial and other capital grants (note 20)
728 1,188 2,941
Impairment and net losses on disposal of fixed assets
(372 ) (1,147 ) (1,991 )
Results from operating activities
209,683 226,528 202,961
Finance income
4,526 7,067 2,682
Finance expenses
(49,660 ) (27,087 ) (29,305 )
Change in fair value of financial instruments (note 32)
(7,593 ) (587 ) (1,268 )
Gains/(losses) on disposal of financial instruments
91 (245 ) —
Exchange gains/(losses)
1,616 (1,733 ) (2,825 )
Net finance expense (note 28)
(51,020 ) (22,585 ) (30,716 )
Share of profit / (loss) of equity accounted investees (note 10)
(879 ) 51 24
Profit before income tax from continuing operations
157,784 203,994 172,269
Income tax expense (note 29)
(42,517 ) (56,424 ) (50,153 )
Profit after income tax from continuing operations
115,267 147,570 122,116
Consolidated profit for the year
115,267 147,570 122,116
Profit attributable to equity holders of the Parent
115,513 147,972 121,728
Profit / (loss) attributable to non-controlling interests (note 19)
(246 ) (402 ) 388
Basic earnings per share (Euros) (note 18)
0.54 0.71 0.58
Diluted earnings per share (Euros) (note 18)
0.54 0.71 0.58
The accompanying notes form an integral part of the consolidated financial statements.

3

GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Statements of Comprehensive Income
for the years ended 31 December 2010, 2009 and 2008
31/12/10 31/12/09
(Expressed in thousands of Euros)
Consolidated profit for the year
115,267 147,570
Income and expenses generated during the year
Measurement of financial instruments (note 11)
0 (14 )
Available-for-sale financial assets
0 (18 )
Tax effect
0 4
Cash flow hedges (note 17 (f))
0 (1,998 )
Cash flow hedges
0 (3,275 )
Tax effect
0 1,277
Translation differences
42,225 (4,145 )
Income and expenses generated during the year
42,225 (6,157 )
Income and expense recognised in the income statement:
Measurement of financial instruments (note 11)
0 172
Available-for-sale financial assets
0 245
Tax effect
0 (73 )
Cash flow hedges (note 17 (f))
197 50
Cash flow hedges
324 80
Tax effect
(127 ) (30 )
Income and expense recognised in the income statement:
197 222
Total comprehensive income for the year
157,689 141,635
Total comprehensive income attributable to the Parent
155,230 140,386
Total comprehensive income attributable to non-controlling interests
2,459 1,249
Total comprehensive income for the year
157,689 141,635
The accompanying notes form an integral part of the consolidated financial statements.

4

GRIFOLS, S.A. AND SUBSIDIARIES
Consolidated Statements of Cash Flows
for the years ended 31 December 2010, 2009 and 2008
31/12/10 31/12/09 31/12/08
(Expressed in thousands of Euros)
Cash flows from/(used in) operating activities
Profit before income tax
157,784 203,994 172,269
Adjustments for:
92,351 61,800 66,034
Amortisation and depreciation (notes 8 and 9)
45,776 39,554 33,256
Other adjustments:
46,575 22,246 32,778
(Profit) /losses on equity accounted investments (note 10)
879 (51 ) (24 )
Exchange differences
(1,616 ) 1,733 2,825
Impairment of assets and net provision charges
913 53 1,994
(Profits) / losses on disposal of fixed assets
(276 ) 1,147 2,001
Government grants taken to income (note 20)
(728 ) (1,188 ) (2,943 )
Net finance expense
47,442 17,551 27,891
Other adjustments
(39 ) 3,001 1,034
Change in operating assets and liabilities
(78,767 ) (104,127 ) (86,550 )
Change in inventories
(18,306 ) (113,104 ) (98,520 )
Change in trade and other receivables
(23,546 ) (12,549 ) (7,951 )
Change in current financial assets and other current assets
(73,022 ) (1,287 ) 405
Change in current trade and other payables
36,107 22,813 19,516
Other cash flows used in operating activities
(67,116 ) (73,487 ) (77,310 )
Interest paid
(40,129 ) (14,719 ) (25,972 )
Interest received
5,436 2,509 2,213
Income tax paid
(32,423 ) (61,277 ) (53,551 )
Net cash from operating activities
104,252 88,180 74,443
Cash flows from/(used in) investing activities
Payments for investments
(108,588 ) (136,626 ) (130,923 )
Group companies and business units
(1,474 ) (15,385 ) (632 )
Property, plant and equipment and intangible assets
(103,402 ) (118,770 ) (129,568 )
Property, plant and equipment
(86,800 ) (103,415 ) (119,824 )
Intangible assets
(16,602 ) (15,355 ) (9,744 )
Other financial assets
(3,712 ) (2,471 ) (723 )
Proceeds from the sale of investments
4,532 673 157
Property, plant and equipment
3,911 673 157
Associates (note 2 ( c))
621 0 0
Net cash used in investing activities
(104,056 ) (135,953 ) (130,766 )
Cash flows from/(used in) financing activities
Proceeds from and payments for equity instruments
(1,250 ) 26,655 (4,212 )
Issue
0 (76 ) 0
Acquisition of own shares (note 17 (d))
(1,250 ) (25,186 ) (4,880 )
Disposal of treasury shares
0 51,917 668
Proceeds from and payments for financial liability instruments
(1,066 ) 344,413 96,349
Issue
118,238 525,078 394,109
Redemption and repayment
(119,304 ) (180,665 ) (297,760 )
Dividends and interest on other equity instruments paid
(27,282 ) (80,913 ) (34,792 )
Other cash flows from financing activities
323 741 0
Other amounts received from financing activities
323 741 0
Net cash from/(used in) financing activities
(29,275 ) 290,896 57,345
Effect of exchange rate fluctuations on cash
19,356 (119 ) (344 )
Net increase / (decrease) in cash and cash equivalents
(9,723 ) 243,004 678
Cash and cash equivalents at beginning of the year
249,372 6,368 5,690
Cash and cash equivalents at end of year
239,649 249,372 6,368
The accompanying notes form an integral part of the consolidated financial statements

5

GRIFOLS, S.A. AND SUBSIDIARIES
Statement of Changes in Consolidated Equity
for the years ended 31 December 2010, 2009 and 2008
(Expressed in thousands of Euros)
Attributable to equity holders of the Parent
Accumulated other comprehensive income
Available-for Equity
Profit attributable sale attributable
Share Share to Interim Own Translation Cash flow financial to Non-controlling
capital premium Reserves * Parent dividend Shares differences hedges assets Parent interests Equity
Balances at 31 December 2007
106,532 131,832 184,608 87,774 0 (28,893 ) (98,516 ) 0 (152 ) 383,185 981 384,166
Translation differences
— — — — — — 14,059 — — 14,059 (104 ) 13,955
Available-for-sale financial assets Gains/(losses)
— — — — — — — (6 ) (6 ) — (6 )
Other comprehensive income for the year
0 0 0 0 0 0 14,059 0 (6 ) 14,053 (104 ) 13,949
Profit for the year
— — — 121,728 — — — — — 121,728 388 122,116
Total comprehensive income for the year
0 0 0 121,728 0 0 14,059 0 (6 ) 135,781 284 136,065
Net movement in own shares
— — 24 — — (4,194 ) — — (4,170 ) — (4,170 )
Other changes
— — — — — — — — 0 (15 ) (15 )
Distribution of 2007 profit
Reserves
— — 63,037 (63,037 ) — — — — — 0 — 0
Dividends
— (10,030 ) — (24,737 ) — — — — — (34,767 ) — (34,767 )
Transaction with owners of the Company
0 (10,030 ) 63,061 (87,774 ) 0 (4,194 ) 0 0 0 (38,937 ) (15 ) (38,952 )
Balances at 31 December 2008
106,532 121,802 247,669 121,728 0 (33,087 ) (84,457 ) 0 (158 ) 480,029 1,250 481,279
Translation differences
— — — — — — (5,796 ) — — (5,796 ) 1,651 (4,145 )
Cash flow hedges
— — — — — — — (1,948 ) — (1,948 ) — (1,948 )
Gains/(Losses) on available-for-sale financial assets
— — — — — — — — 158 158 — 158
Other comprehensive income for the year
0 0 0 0 0 0 (5,796 ) (1,948 ) 158 (7,586 ) 1,651 (5,935 )
Profit/(loss) for the year
— — — 147,972 0 — — — — 147,972 (402 ) 147,570
Total comprehensive income for the year
0 0 0 147,972 0 0 (5,796 ) (1,948 ) 158 140,386 1,249 141,635
Net movement in own shares
— — (5,679 ) — 32,410 — — — 26,731 — 26,731
Other changes
— — (124 ) — — — — — (124 ) 44 (80 )
Business combinations
— — — — — — — — 0 9,876 9,876
Distribution of 2008 profit
Reserves
— — 73,037 (73,037 ) — — — — — 0 — 0
Dividends
— — — (48,691 ) — — — — — (48,691 ) (54 ) (48,745 )
Interim dividend
— — — — (31,960 ) — — — — (31,960 ) (208 ) (32,168 )
Transaction with owners of the Company
0 0 67,235 (121,728 ) (31,960 ) 32,410 0 0 0 (54,044 ) 9,658 (44,386 )
Balance at 31 December 2009
106,532 121,802 314,903 147,972 (31,960 ) (677 ) (90,253 ) (1,948 ) 0 566,371 12,157 578,528
Translation differences
0 0 0 0 0 0 39,520 0 0 39,520 2,705 42,225
Cash flow hedges
0 0 0 0 0 0 0 197 0 197 0 197
Other comprehensive income for the year
0 0 0 0 0 0 39,520 197 0 39,717 2,705 42,422
Profit/(loss) for the year
0 0 0 115,513 0 0 0 0 0 115,513 (246 ) 115,267
Total comprehensive income for the year
0 0 0 115,513 0 0 39,520 197 0 155,230 2,459 157,689
Net movement in own shares
0 0 0 0 0 (1,250 ) 0 0 0 (1,250 ) (1,250 )
Other changes
0 0 (82 ) 0 0 0 0 0 0 (82 ) (213 ) (295 )
Distribution of 2009 profit
Reserves
0 0 88,783 (88,783 ) 0 0 0 0 0 0 0
Dividends
0 0 0 (27,229 ) 0 0 0 0 0 (27,229 ) (53 ) (27,282 )
Interim dividend
0 0 0 (31,960 ) 31,960 0 0 0 0 0 0
Transaction with owners of the Company
0 0 88,701 (147,972 ) 31,960 (1,250 ) 0 0 0 (28,561 ) (266 ) (28,827 )
Balance at 31 December 2010
106,532 121,802 403,604 115,513 0 (1,927 ) (50,733 ) (1,751 ) 0 693,040 14,350 707,390
*      Reserves include accumulated earnings, legal reserves and other reserves
The accompanying notes form an integral part of the consolidated financial statements

6

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(1) Nature, Principal Activities and Subsidiaries
(a) Grifols, S.A.
Grifols, S.A. (hereinafter the Company) was incorporated with limited liability under Spanish law on 22 June 1987. Its registered and tax offices are in Barcelona. The Company’s statutory activity consists of providing corporate and business administrative, management and control services, as well as investing in assets and property. The Company’s principal activity consists of rendering administrative, management and control services to its subsidiaries.
On 17 May 2006 the Company completed its flotation on the Spanish stock market which was conducted through the public offering of 71,000,000 ordinary shares of Euros 0.50 par value each and a share premium of Euros 3.90 per share. The total capital increase (including the share premium) amounted to Euros 312.4 million, equivalent to a price of Euros 4.40 per share.
With effect as of 2 January 2008 the Company’s shares were floated on the Spanish stock exchange’s IBEX-35 index.
All of the Company’s shares are listed on the Barcelona, Madrid, Valencia and Bilbao stock exchanges and on the electronic stock market.
Grifols, S.A. is the parent company of the subsidiaries listed in section 1(b) of these Notes.
Grifols, S.A. and subsidiaries (hereinafter the Group) act on an integrated basis and under common management and their principal activity is the procurement, manufacture, preparation and sale of therapeutic products, especially haemoderivatives.
The main business locations of the Group’s Spanish companies are in Barcelona, Parets del Vallés (Barcelona) and Torres de Cotilla (Murcia), while the American companies’ installations are located in Los Angeles, California (USA).

1

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(b) Subsidiaries
The Group companies are grouped into three areas: industrial, commercial and services.
- Industrial area
The following companies are included:
Diagnostic Grifols, S.A. which has registered offices in Parets del Vallès (Barcelona), Spain and was incorporated into the Group on 24 March 1987, and is engaged in the development and manufacture of diagnostic equipment, instrumentation and reagents.
Instituto Grifols, S.A . which has registered offices in Parets del Vallès (Barcelona), Spain, and was incorporated into the Group on 21 September 1987, carries out its activities in the area of bioscience and is engaged in plasma fractioning and the manufacture of haemoderivative pharmaceutical products.
Laboratorios Grifols, S.A., with registered offices in Parets del Vallès (Barcelona), Spain, was incorporated into the Group on 18 April 1989 and is engaged in the production of glass- and plastic-packaged parenteral solutions, parenteral and enteral nutrition products and blood extraction equipment and bags. Its production facilities are in Barcelona and Murcia.
Biomat, S.A., with registered offices in Parets del Vallès (Barcelona), Spain, was incorporated into the Group on 30 July 1991. It operates in the field of bioscience and basically engages in analysis and certification of the quality of plasma used by Instituto Grifols, S.A. It also provides transfusion centres with plasma virus inactivation services.
Grifols Engineering, S.A., with registered offices in Parets del Vallès (Barcelona), Spain, was incorporated into the Group on 14 December 2000 and is engaged in the design and development of the Group’s manufacturing installations and part of the equipment and machinery used at these premises. The company also renders engineering services to third parties.
Logister, S.A. was incorporated with limited liability under Spanish law on 22 June 1987 and its registered offices are at Polígono Levante, calle Can Guasch, s/n, 08150 Parets del Vallés, Barcelona. Its activity comprises the manufacture, sale and purchase, marketing and distribution of all types of computer products and materials. 99.985% of this company is solely-owned directly by Movaco, S.A., another subsidiary.

2

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Biomat USA, Inc ., with registered offices at 1209, Orange Street, Wilmington, New Castle (Delaware Corporation) (USA), was incorporated into the Group on 1 March 2002 and carries out its activities in the area of bioscience, procuring human plasma. Since 1 November 2007, this company’s share capital is held by Instituto Grifols, S.A. and Grifols, Inc.
Grifols Biologicals, Inc., with registered offices at 15 East North Street, Dover, (Delaware) (USA), was incorporated into the Group on 15 May 2003 and is exclusively engaged in plasma fractioning and the production of haemoderivatives. Grifols, Inc. directly owns 100% of this company.
PlasmaCare, Inc., with registered offices at 1209 Orange Street, County of New Castle, Wilmington, Delaware 19801, was incorporated into the Group on 3 March 2006 and carries out its activities in the area of bioscience, procuring human plasma. Since 1 November 2007, this company’s share capital is held by Instituto Grifols, S.A. and Grifols, Inc.
Plasma Collection Centers, Inc., with registered offices at 1209 Orange Street, County of New Castle, Wilmington, Delaware 19801 (USA) and incorporated on 2 March 2007. Its activity, developed in the bioscience area, consists of procuring human plasma. 100% of this company’s share capital is held directly by Biomat USA, Inc. In January 2010 Plasma Collection Centers, Inc. merged with Biomat USA, Inc., having no impact on the Group.
Lateral Grifols Pty Ltd. (formerly Diamed Australia Pty Ltd.), with registered offices at Unit 5/80 Fairbank, Clayton South, Victoria 3149 (Australia), was incorporated into the Group on 3 March 2009. Its activity consists of the distribution of pharmaceutical products and the development and manufacture of reagents for diagnostics. This company is directly and fully owned by Woolloomooloo Holdings Pty Ltd.
Medion Grifols Diagnostic AG, with registered offices at Bonnstrasse, 9, 3186 Düdingen, Switzerland, was incorporated into the Group on 3 March 2009. The Company’s statutory activity consists of development and production in the biotechnology and diagnostic sectors. 80% of this company is directly held by Saturn Investments AG.
- Commercial area
The companies responsible for the marketing and distribution of, mainly, products manufactured by the industrial area companies are all grouped in the commercial area.

3

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Movaco, S.A. was incorporated with limited liability under Spanish law on 21 July 1987 and its registered offices are at Polígono Levante, calle Can Guasch, s/n, 08150 Parets del Vallés, Barcelona. Its principal activity is the distribution and sale of reagents, chemical products and other pharmaceutical specialities, and of medical-surgical materials, equipment and instruments for use in laboratories and healthcare centres.
Grifols International, S.A., with registered offices in Parets del Vallès (Barcelona), Spain, was incorporated into the Group on 4 June 1997. This company directs and coordinates the marketing, sales and logistics for all the Group’s commercial subsidiaries. Products are marketed through subsidiaries operating in different countries. These subsidiaries, their registered offices and date of incorporation into the Group, are listed below.
Grifols Portugal Productos Farmacéuticos e Hospitalares, Lda., was incorporated with limited liability under Portuguese law on 10 August 1988. Its registered offices are at Jorge Barradas, 30 —c R/C, 1500 Lisbon (Portugal) and it imports, exports and markets pharmaceutical and hospital equipment and products particularly Grifols products. 99.99% of this company is owned directly by Movaco, S.A.
Grifols Chile, S.A. was incorporated under limited liability in Chile on 2 July 1990. Its registered offices are at calle Avda. Americo Vespucio 2242, Comuna de Conchali, Santiago de Chile (Chile). Its statutory activity comprises the development of pharmaceutical businesses, which can involve the import, production, marketing and export of related products.
Grifols Argentina, S.A. was incorporated with limited liability in Argentina on 1 November 1991 and its registered offices are at Bartolomé Mitre 1371, fifth floor office “P” (CP 1036), Buenos Aires (Argentina). Its statutory activity consists of clinical and biological research, the preparation of reagents and therapeutic and diet products, the manufacture of other pharmaceutical specialities and the marketing thereof.
Grifols s.r.o. was incorporated with limited liability under Czech Republic law on 15 December 1992. Its registered offices are at Zitná 2, Praga (Czech Republic) and its statutory activity consists of the purchase, sale and distribution of chemical-pharmaceutical products, including human plasma.

4

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Logistica Grifols, S.A. de C.V. (formerly Grifols México, S.A. de C.V.) was incorporated with limited liability under Mexican law on 9 January 1970, with registered offices at calle Eugenio Cuzin nº 909, Parque Industrial Belenes Norte, 45150 Zapopan, Jalisco (Mexico). Its statutory activity comprises the manufacture and marketing of pharmaceutical products for human and veterinary use. On 6 May 2008 Grifols Mexico S.A. de C.V. was spun off into two companies and its name was changed to Logística Grifols, S.A. de C.V.
Grifols México, S.A. de C.V. was incorporated with limited liability under Mexican law on 6 May 2008, as a result of the spin off of the former company Grifols Mexico, S.A. de C.V. Its registered offices are at calle Eugenio Cuzin nº 909, Parque Industrial Belenes Norte, 45150 Zapopan, Jalisco (Mexico). Its statutory activity comprises the production, manufacture, adaptation, conditioning, sale and purchase, commissioning, representation and consignment of all kinds of pharmaceutical products and the acquisition of machinery, equipment, raw materials, tools, assets and property for the aforementioned purposes.
Grifols USA, LLC. was incorporated in the State of Florida (USA) on 19 April 1990. Its registered offices are at 8880 N.W. 18 Terrace, Miami, Florida (USA) and its statutory activity is any activity permitted by US legislation. This company is 100% directly owned by Grifols Biologicals, Inc.
Grifols Italia S.p.A . has its registered offices at Via Carducci 62 d, 56010 Ghezzano, Pisa (Italy) and its statutory activity comprises the purchase, sale and distribution of chemical-pharmaceutical products. 66.66% of this company was acquired on 9 June 1997 and the remaining 33.34% on 16 June 2000.
Grifols UK Ltd., the registered offices of which are at 72, St. Andrew’s Road, Cambridge CB4 1G (United Kingdom), is engaged in the distribution and sale of therapeutic and other pharmaceutical products, especially haemoderivatives. 66.66% of this company was acquired on 9 June 1997 and the remaining 33.34% on 16 June 2000.
Grifols Deutschland GmbH was incorporated with limited liability under German law on 21 May 1997, with registered offices at Siemensstrasse 32, D-63225 Langen (Germany). Its statutory activity consists of the import, export, distribution and sale of reagents, chemical and pharmaceutical products, especially to laboratories and healthcare centres, and medical and surgical materials, equipment and instruments for laboratory use.

5

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Grifols Brasil, Ltda. was incorporated with limited liability in Brazil on 4 May 1998. Its registered offices are at Rua Marechal Hermes 247, Centro Cívico, CEP 80530-230, Curitiba (Brazil). Its statutory activity consists of the import and export, preparation, distribution and sale of pharmaceutical and chemical products for laboratory and hospital use, and medical-surgical equipment and instrumentation.
Grifols France, S.A.R.L. was incorporated with limited liability under French law on 2 November 1999, with registered offices at Centre d’affaires auxiliares system, Bat. 10, Parc du Millenaire — 125, Rue Henri Becquerel, 34036, Montpellier (France). Its statutory activity is the marketing of chemical and healthcare products.
Alpha Therapeutic Italia, S.p.A. was incorporated on 3 July 2000, with registered offices at Piazza Meda 3, 20121 Milan (Italy), and engages in the distribution and sale of therapeutic products, especially haemoderivatives.
Grifols Asia Pacific Pte, Ltd was incorporated on 10 September 1986 , with registered offices at 501 Orchard Road #20-01 Wheelock Place, Singapore, and its activity consists of the distribution and sale of medical and pharmaceutical products.
Grifols Malaysia Sdn Bhd is partly owned (30%) by Grifols Asia Pacific Pte, Ltd. The registered offices of this company are in Selangor (Malaysia) and it engages in the distribution and sale of pharmaceutical products.
Grifols (Thailand) Ltd was incorporated on 1 September 1995 and its registered offices are at 287 Liberty Square Level 8, Silom Road, Bangkok. Its activity comprises the import, export and distribution of pharmaceutical products. 48% of this company is directly owned by Grifols Asia Pacific Pte., Ltd.
Grifols Polska Sp.z.o.o. was incorporated on 12 December 2003, with registered offices at UL. Nowogrodzka, 68, 00-116, Warsaw, Poland, and engages in the distribution and sale of pharmaceutical, cosmetic and other products.
Australian Corporate Number 073 272 830 Pty Ltd. (formerly Lateral Grifols Diagnostics Pty Ltd.), with registered offices at Unit 5/80 Fairbank, Clayton South, Victoria 3149 (Australia) was incorporated into the Group on 3 March 2009. Its activity comprises the distribution of pharmaceutical products and reagents for diagnostics. This company is 100% directly held by Woolloomooloo Holdings Pty Ltd.

6

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Medion Diagnostics GmbH with registered offices at Lochhamer Schlag 12 D-82166 Gräfelfing (Germany), was incorporated into the Group on 3 March 2009. The Company’s statutory activity consists of the distribution and sale of biotechnological and diagnostic products. This company is directly and fully owned by Medion Grifols Diagnostic AG.
Grifols Nordic, AB (formerly Xepol, AB) with registered offices in Engelbrekts Kyrkogata 7B 114 26 Stockhom, Sweden, was incorporated into the Group on 3 June 2010. Its activity consists of research and development, production and marketing, either directly or through subsidiaries, of pharmaceutical products, medical devices and any other asset deriving from the aforementioned activities. This company is 100% directly owned by Grifols, S.A.
Grifols Colombia, Ltda , with registered offices at Cra 7 71-52 TBP 9 Cundinamarca, Bogota, Colombia, was incorporated on 3 June 2010. Its activity consists of the sale, commercialisation and distribution of medicines, pharmaceutical (including but not limited to haemoderivatives) and hospital products, medical devices, biomedical equipment, laboratory instruments and reactives for diagnosis and/or sanitary software.
- Services area
The following companies are included in this area:
Grifols, Inc. was incorporated on 15 May 2003 with registered offices at 15 East North Street, Dover (Delaware, USA). Its principal activity is the holding of investments in Group companies.
Grifols Viajes, S.A., with registered offices in Barcelona, Spain, was incorporated into the Group on 31 March 1995 and operates as a retail travel agency exclusively serving Group companies.
Squadron Reinsurance Ltd ., with registered offices in Dublin, Ireland, was incorporated into the Group on 25 April 2003 and engages in the reinsurance of Group companies’ insurance policies.
Arrahona Optimus, S.L., with registered offices in Barcelona, Spain, was incorporated into the Group on 28 August 2008. The Company’s statutory activity is the development and construction of offices and business premises. Its only asset is the office complex located in the municipality of Sant Cugat del Vallés.

7

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Gri-Cel, S.A., with registered offices at Avenida de la Generalitat 152, Sant Cugat del Vallés (Barcelona), was incorporated on 9 November 2009. The Company’s statutory activity consists of research and development in the field of regenerative medicine, awarding of research grants, subscription to collaboration agreements with entities and participation in projects in the area of regenerative medicine.
Saturn Australia Pty Ltd., with registered offices at Unit 5/80 Fairbank, Clayton South, Victoria 3149 (Australia), was incorporated into the Group on 3 March 2009. Its activity consists of holding shares and investments. This company is directly and fully owned by Woolloomooloo Holdings Pty Ltd.
Saturn Investments AG, with registered offices at c/o Dr. Christoph Straub, Hanibuel 8, CH 6300 Zug (Switzerland) was incorporated into the Group on 3 March 2009. Its activity consists of the holding of shares. This company is directly and fully owned by Saturn Australia Pty Ltd.
Woolloomooloo Holdings Pty Ltd., with registered offices at Unit 5/80 Fairbank, Clayton South, Victoria 3149 (Australia), was incorporated into the Group on 3 March 2009. Its activity consists of holding shares. 49% of this holding company is directly held by Grifols, S.A.
(c) Associates and other participations
Quest Internacional, Inc, 35% owned by Diagnostic Grifols, S.A., with registered offices in Miami, Florida (USA), engages in the manufacture and marketing of reagents and clinical analysis instruments. On 9 November 2010 the Group sold the interest it held in this company.
UTE Salas Blancas , a joint venture participated in 50% by Grifols Engineering, S.A. was formed in 2009 and is domiciled at calle Mas Casanovas 46, Barcelona. Its statutory activity consists of the drafting of the project, execution of works and installation of clean rooms and other facilities in the Banc de Sang i Teixits (blood and tissue bank) wing of a hospital.
Nanotherapix, S.L. was incorporated on 25 June 2009 and is 51% owned by Gri-Cel, S.A. through a share capital increase carried out on 9 March 2010. This company is domiciled at Avenida Generalitat 152, San Cugat del Valles, Barcelona and its activity consists of the development, validation and production of the technology required to implement the use of genetic and cellular therapy for the treatment of human and animal pathologies.

8

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(2) Basis of Presentation of the Consolidated Financial Statements
The accompanying consolidated financial statements have been authorised for issue by the directors of Grifols, S.A. on the basis of the accounting records of Grifols, S.A. and of the Group companies. The accompanying consolidated financial statements for 2010, 2009 and 2008 have been prepared under International Financial Reporting Standards, as issued by the International Accounting Standard Board (IFRS-IASB) to present fairly the consolidated equity and consolidated financial position of Grifols, S.A. and subsidiaries at 31 December 2010 and 2009, as well as the consolidated results from their operations, consolidated comprehensive income, consolidated cash flows and changes in consolidated equity for the three-year period then ended.
The Group adopted EU-IFRS for the first time on 1 January 2004 and has been preparing its consolidated annual accounts under International Financial Reporting Standards, as adopted by the European Union (IFRS-EU) as required by Capital markets regulations governing the presentation of financial statements by companies whose debt or own equity instruments are listed on a regulated market.
The Group’s consolidated financial statements for 2010, 2009 and 2008 have been prepared under International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board, and in the case of Grifols, S.A. and subsidiaries do not differ from IFRS as adopted by the European Union taking into account all mandatory accounting policies and rules and measurement bases with material effect, as well as the alternative treatments permitted by the relevant standards in this connection.
(a) Changes to IFRS in 2010, 2009 and 2008
In accordance with IFRSs, the following should be noted in connection with the scope of application of IFRS and the preparation of these consolidated financial statements of the Group.
Effective date in 2008
Standards that have not affected the Group
- Amendment to IAS 39 Reclassification of Financial Assets: Effective Date and Transition (effective date 1 July 2008).
- IFRIC 16 Hedges of a Net Investment in a Foreign Operation (effective date 1 October 2008).
- IFRIC 12 Service Concession Arrangements (effective date 1 January 2008).
- IFRIC 14 IAS 19 The Limit of a Defined Benefit Asset, Minimum Funding Requirements and their Interaction (effective date 1 January 2008)
- Amendments to IAS 39 and IFRS 7: Reclassification of Financial Instruments (effective date 1 July 2008).

9

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Effective date in 2009
a) Standards effective as of 1 January 2009 that have required changes to accounting policies and presentation
- IAS 1 Presentation of Financial Statements (revised 2007) (annual periods beginning on or after 1 January 2009). This standard modifies the requirements for presentation of the financial statements, introducing the statement of comprehensive income, which comprises income and other comprehensive income. Entities may also present two separate statements, an income statement showing profit or loss for the year and a statement of other comprehensive income presenting profit or loss for the year and other comprehensive income. When an entity changes an accounting policy retrospectively or makes a retrospective reclassification of items in its financial statements, it must also present a statement of financial position (balance sheet) as at the beginning of the earliest comparative period.
- IFRS 8 Operating Segments (annual periods beginning on or after 1 January 2009). The impact of this standard mainly relates to the disclosure of financial information by segment. See note 6.
- IAS 23 Borrowing Costs (revised 2007) (annual periods beginning on or after 1 January 2009). This is a change in accounting policy. The Group applies this standard to borrowing costs related to qualifying assets capitalised on or subsequent to the date this standard became effective. The standard eliminates the possibility of recognising these borrowing costs as an expense, stipulating that borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset form part of the cost of that asset. Since 1 January 2009 the Group has capitalised interest amounting to Euros 1,278 thousand (see note 26).
- Amendments to IFRS 7: “Improving Disclosures about Financial Instruments” (applicable for years beginning on or after 1 January 2009).
b) Standards effective as of 1 January 2009 that have not affected the Group
- IFRIC 13 Customer Loyalty Programmes (annual periods beginning after 31 December 2008).
- IFRS 2 Share-Based Payment: Modifications to vesting conditions and cancellations (applied retrospectively to annual periods beginning on or after 1 January 2009).
- IAS 32 Financial Instruments: Presentation and IAS 1: Presentation of Financial Statements: Changes to puttable financial instruments and obligations arising on liquidation (effective as of 1 January 2009).

10

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
- Improvements to IFRSs. This document modifies various standards and is effective for years beginning on or after 1 July 2009.
- IFRS 1 First-time Adoption of International Financial Reporting Standards and IAS 27 Consolidated and Separate Financial Statements: These changes relate to the measurement of investments in separate financial statements. This standard is applied prospectively for years started on or after 1 January 2009.
- Embedded derivatives: Amendments to IFRIC 9 and IAS 39 (applicable for years started after 31 December 2008).
- IFRS 1 First-time Adoption of International Financial Reporting Standards (applicable to annual periods beginning after 31 December 2009). This change does not affect the Group.
- IFRIC 15 Agreements for the Construction of Real Estate.
- IFRIC 17 Distribution of Non-Cash Assets to Owners (effective date: 1 July 2009).
- IFRIC 18 Transfers of Assets from Customers (effective date: 1 July 2009).
- IAS 39 Financial Instruments: Recognition and Measurement. Changes to the items that can be classified as hedged. The amendment clarifies the types of risks that can be classified as hedged when applying hedge accounting (effective date: 1 July 2009).
Effective date in 2010
- Amendment to IFRS 2 Group Cash-settled Share Based Payment Transactions (effective date: 1 January 2010).
- 2009 improvements to IFRSs (effective date: 1 January 2010).
- Amendment to IAS 32 Financial Instruments: Presentation, Classification of Rights Issues (effective date: 1 February 2010).
- IFRIC 19 Extinguishing financial liabilities with equity instruments (effective date: 1 July 2010).
- Amendment to IFRS 1 Limited Exemption from Comparative IFRS 7 Disclosures for First-time Adopters (effective date: 1 July 2010).
- IFRS 3 Amendments resulting from May 2010 Annual Improvements (effective date: 1 July 2010).

11

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
- IAS 27 Amendments resulting from May 2010 Annual Improvements (effective date: 1 July 2010).
In accordance with the new IFRS 3 (mandatory application in years starting after 1 July 2009), transaction costs, which differ from costs of issuing debt or equity instruments, are recognised as an expense as incurred. The application of this new standard has an impact on the consolidated financial statements of the Grifols Group (see note 15).
The application of the other standards has not had a significant impact on the Group’s consolidated financial statements or has not been applicable.
Standards issued but not effective on 2010
- IAS 24 Revised Related Party Disclosures
- Amendment to IFRIC 14: Prepayment of a minimum funding requirement (effective date: 1 January 2011).
- IFRS 7 Amendments resulting from May 2010 Annual Improvements (effective date: 1 January 2011).
- Amendment to IFRIC 13 Customer Loyalty Programmes (effective date: 1 January 2011).
- IAS 34 Amendments resulting from May 2010 Annual Improvements (effective date: 1 January 2011).
- IAS 1 Amendments resulting from May 2010 Annual Improvements (effective date: 1 January 2011).
The Group has not applied any of the standards or interpretations issued prior to their deadline. The Company’s directors do not expect that the entry into force of these modifications will have a significant effect on the consolidated financial statements.

12

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(b) Relevant accounting estimates, assumptions and judgements used when applying accounting principles
The preparation of consolidated financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of Group accounting policies. A summary of the items requiring a greater degree of judgement or complexity, or where the assumptions and estimates made are significant to the preparation of the consolidated financial statements, are as follows:
• The assumptions used for calculation of the fair value of financial instruments (see note 4 (k)).
• Measurement of assets and goodwill to determine any related impairment losses (see note 4(i)).
• Useful lives of property, plant and equipment and intangible assets (see notes 4(g) and 4(h)).
• Evaluation of the capitalisation of development costs (see note 4(h)).
• Evaluation of provisions and contingencies (see note 4(r)).
• Evaluation of the effectiveness of hedging (see note 4(l) and 17 (f)).
• The application of the definition of a business (see note 4(b)).

13

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(c) Consolidation
The percentages of direct or indirect ownership of subsidiaries by the Company at 31 December 2010, 2009 and 2008, as well as the consolidation method used in each case for preparation of the accompanying consolidated financial statements, are detailed below:
31/12/10 31/12/09 31/12/08
Percentage ownership Percentage ownership Percentage ownership
Direct Indirect Direct Indirect Direct Indirect
Parent
Grifols, S.A.
Fully-consolidated companies
Laboratorios Grifols, S.A.
99.998 0.002 99.998 0.002 99.998 0.002
Instituto Grifols, S.A.
99.998 0.002 99.998 0.002 99.998 0.002
Movaco, S.A.
99.999 0.001 99.999 0.001 99.999 0.001
Grifols Portugal Productos
Farmacéuticos e Hospitalares, Lda.
0.010 99.990 0.015 99.985 0.015 99.985
Diagnostic Grifols, S.A.
99.998 0.002 99.998 0.002 99.998 0.002
Logister,S.A.
— 100.000 — 100.000 — 100.000
Grifols Chile,S.A.
99.000 — 99.000 — 99.000 —
Biomat,S.A.
99.900 0.100 99.900 0.100 99.900 0.100
Grifols Argentina,S.A.
99.260 0.740 100.000 — 100.000 —
Grifols,s.r.o.
100.000 — 100.000 — 100.000 —
Logistica Grifols S.A de C.V
99.990 0.010 100.000 — 100.000 —
Grifols México,S.A. de C.V.
99.990 0.010 100.000 — 100.000 —
Grifols Viajes,S.A.
99.900 0.100 99.900 0.100 99.900 0.100
Grifols USA, LLC.
— 100.000 — 100.000 — 100.000
Grifols International,S.A.
99.900 0.100 99.900 0.100 99.900 0.100
Grifols Italia,S.p.A.
100.000 — 100.000 — 100.000 —
Grifols UK,Ltd.
100.000 — 100.000 — 100.000 —
Grifols Deutschland,GmbH
100.000 — 100.000 — 100.000 —
Grifols Brasil,Ltda.
100.000 — 100.000 — 100.000 —
Grifols France,S.A.R.L.
99.000 1.000 99.000 1.000 99.000 1.000
Grifols Engineering, S.A.
99.950 0.050 99.950 0.050 99.950 0.050
Biomat USA, Inc.
— 100.000 — 100.000 — 100.000
Squadron Reinsurance Ltd.
100.000 — 100.000 — 100.000 —
Grifols Inc.
100.000 — 100.000 — 100.000 —
Grifols Biologicals Inc.
— 100.000 — 100.000 — 100.000
Alpha Therapeutic Italia, S.p.A.
100.000 — 100.000 — 100.000 —
Grifols Asia Pacific Pte., Ltd.
100.000 — 100.000 — 100.000 —

14

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
31/12/10 31/12/09 31/12/08
Percentage ownership Percentage ownership Percentage ownership
Direct Indirect Direct Indirect Direct Indirect
Grifols Malaysia Sdn Bhd
— 30.000 — 30.000 — 30.000
Grifols (Thailand) Ltd.
— 48.000 — 48.000 — 48.000
Grifols Polska Sp.z.o.o.
100.000 — 100.000 — 100.000 —
Plasmacare, Inc.
— 100.000 — 100.000 — 100.000
Plasma Collection Centers, Inc.
— — — 100.000 — 100.000
Arrahona Optimus S.L.
99.995 0.005 100.000 — 100.000 —
Woolloomooloo Holdings Pty Ltd.
49.000 — 49.000 — — —
Lateral Grifols Pty Ltd.
— 49.000 — 49.000 — —
Australian Corporate Number 073 272 830 Pty Ltd
— 49.000 — 49.000 — —
Saturn Australia Pty Ltd.
— 49.000 — 49.000 — —
Saturn Investments AG
— 49.000 — 49.000 — —
Medion Grifols Diagnostic AG
— 39.200 — 39.200 — —
Medion Diagnostics GmbH
— 39.200 — 39.200 — —
Gri-Cel, S.A.
0.001 99.999 0.001 99.999 — —
Grifols Colombia, Ltda.
99.000 1.000 — — — —
Grifols Nordic AB
100.000 — — — — —
31/12/10 31/12/09 31/12/08
Percentage ownership Percentage ownership Percentage ownership
Direct Indirect Direct Indirect Direct Indirect
Companies accounted for using the equity method
Quest International, Inc.
— — — 35.000 — 35.000
Nanotherapix, S.L
— 51,000 — — — —
Subsidiaries in which the Company directly or indirectly owns the majority of equity or voting rights have been fully consolidated. Associates in which the Company owns between 20% and 50% of share capital and has no power to govern the financial or operating policies of these companies have been accounted for under the equity method.
Although the Group holds 30% of the shares with voting rights of Grifols Malaysia Sdn Bhd, it controls the majority of the profit-sharing and voting rights of Grifols Malaysia Sdn Bhd through a contract with the other shareholder and a pledge on its shares.
Grifols (Thailand) Ltd. has two classes of shares and it grants the majority of voting rights to the class of shares held by the Group.

15

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The Group holds 99% of the voting rights in its Australian and Swiss subsidiaries.
On 9 March 2010 one of the Group companies acquired 51% of Nanotherapix, S.L., a technologically based company which engages in advisory services, training of researchers, design and development of technologies, services, know-how, molecules and products applied to biotechnology, biomedicine and pharmaceutical fields. The investment has been made through a share capital increase of Euros 1,474 thousand in 2010 and between 2011 and 2014 successive contributions will be made through additional yearly share capital increases amounting to Euros 1,472 thousand. These contributions are dependent on certain shareholders of Nanotherapix, S.L. performing research advisory and management tasks for this company. The acquisition of Nanotherapix, S.L. has been treated as an equity-accounted joint venture, as the company’s strategic and operational decisions require unanimous consent of the parties sharing control and Grifols does not have the majority vote in the board of directors. Due to the losses incurred by Nanotherapix, S.L., impairment has been made for part of the investment in 2010 (see note 10).
On 3 June 2010 the Group acquired 100% of Xepol AB (now Grifols Nordic AB) which holds the intellectual property rights for the treatment of the post-polio syndrome which includes patents for the USA, Europe and Japan for a specific method of treatment for this syndrome using intravenous immunoglobulin (haemoderivative). The sum paid for this acquisition amounted to Euros 2,255 thousand. The assets acquired and liabilities assumed do not constitute a business pursuant to the definition provided in IFRS 3 and, therefore, the transaction has been recognised as the acquisition of an intangible asset.
On 9 November 2010 the Group sold the 35% interest it held in the US company Quest International, Inc. for a sales price of Euros 621 thousand.
(3) Business Combinations
(a) Acquisition of plasma collection centre from AmeriHealth Plasma LLC.
On 1 April 2008 the Group acquired through Biomat USA, Inc. a plasma collection centre in the USA from AmeriHealth Plasma LLC.
The business combination cost included a contingent price of Euros 1,328 thousand based on the number of litres of certain products obtained during the following three years. The contingent price has been determined based on the present value of the estimated payments during the aforementioned period. In 2009 the estimated contingent price increased by Euros 225 thousand.

16

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Details of the aggregate business combination cost and fair value of the net assets acquired and goodwill at the acquisition date are as follows:
Thousands of Euros
2009 2008
Cost of the business combination
Cash paid
632 632
Fair value of deferred payment
1,968 1,743
2,600 2,375
Fair value of net assets acquired
3 3
Goodwill
2,597 2,372
(see note 7 ) (see note 7 )
Goodwill generated in the acquisition is attributed to the blood donors list of the plasma centre, an intangible which is not a contractual or separable asset and other expected benefits from the business combination related with the assets and activities of the Group.
Had the acquisition taken place at 1 January 2008, the Group’s revenue and consolidated profit for the year would not have varied significantly. The profit generated between the acquisition date and 31 December 2008 is immaterial.
(b) Acquisition of Australian-Swiss group
On 3 March 2009 the Group acquired 49% of the economic rights and 99% of the voting rights in a holding company of the Australian-Swiss group Woolloomooloo Holdings Pty Ltd, thereby gaining control of this group, for Euros 25 million through a share capital increase fully subscribed by Grifols, S.A.
Details of the aggregate business combination cost, the fair value of the net assets acquired and goodwill at the acquisition date were follows:
Thousands of Euros
Cost of the business combination
Cash paid
25,000
Fair value of deferred payment
497
Total cost of the business combination
25,497
Fair value of net assets acquired
9,307
Goodwill
16,190
(see note 7 )

17

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Although at 3 March 2009 not all the information necessary to allocate the purchase price correctly between the different balance sheet captions used in the business combination was available to the Group, further information was obtained at 31 December 2009 which made it possible to allocate assets and liabilities more accurately in accordance with the amounts indicated in the table above. Upon completion of the analysis, no changes have arisen to the estimate made at 31 December 2009.
Goodwill generated in the acquisition is attributed to the synergies and other expected benefits from the business combination of the assets and activities of the Group.
The Australian-Swiss Group provides the commercial strength required by Grifols to consolidate and increase its presence in the diagnostic markets of Australia and New Zealand, which until this acquisition consisted only of the sale of instruments through distributors.
After obtaining the licence for Flebogamma DIF in Australia (next generation IVIG), Grifols haemoderivatives began to be commercialised in this country.
Grifols’s investment also included the acquisition under the same terms, of Medion, located in Switzerland, which has developed new technology for determining blood groups, supplementary to that used by Grifols.
Had the acquisition taken place at 1 January 2009, the Group’s revenue and consolidated profit for the period would not have varied significantly. Accumulated losses incurred by the Australian-Swiss group attributable to the Group results from the date of acquisition to 31 December 2009 amounted to Euros 652 thousand.

18

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
At the date of acquisition the amounts of recognised assets, liabilities and contingent liabilities are as follows:
Thousands of Euros
Fair value Book value
Intangible assets (note 8)
6,525 476
Property, plant and equipment (note 9)
2,307 3,113
Deferred tax assets (note 29)
500 258
Inventories (note 12)
3,549 3,549
Trade and other receivables
2,096 2,096
Other assets
293 293
Cash and cash equivalents
10,112 10,112
Total assets
25,382 19,897
Trade and other payables
3,165 3,165
Other liabilities
1,273 1,272
Deferred tax liabilities (note 29)
1,761 551
Total liabilities and contingent liabilities
6,199 4,988
Total net assets
19,183 14,909
Non-controlling interests (note 19)
(9,876 )
Total net assets acquired
9,307
Goodwill (note 7)
16,190
Cash paid
25,497
Cash and cash equivalents of the acquired company
(10,112 )
Cash outflow for the acquisition
15,385
Intangible assets were measured at fair value. The royalty relief method has been used to measure certain patents acquired by the Group. An 8% royalty was considered, together with a discount rate after tax of 10%. Patents were measured on the basis of projected sales for a fifteen-year period.

19

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(4) Accounting and Valuation Principles Applied
(a) Subsidiaries
Subsidiaries are entities, including special purpose entities (SPE), over which the Group exercises control, either directly or indirectly through other subsidiaries. Control is the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. In assessing control, potential voting rights held by the Group or other entities that are exercisable or convertible at the end of each reporting period are considered.
Information on subsidiaries forming the consolidated Group is included in note 2 (c).
The income, expenses and cash flows of subsidiaries are included in the consolidated financial statements from the date of acquisition, which is when the Group takes control, until the date that control ceases.
All significant balances and transactions as well as any unrealised gains or losses are eliminated in the consolidation process.
The accounting principles and criteria used by subsidiaries have been consistent with those applied by the Company in the preparation of the consolidated financial statements.
The financial statements of subsidiaries refer to the same date and the same reporting period as the financial statements of Grifols, S.A.
(b) Business combinations
As permitted by IFRS 1: First-time Adoption of International Financial Reporting Standards, the Group has recognized only business combinations that occurred on or after 1 January 2004, date of transition to IFRS, using the acquisition method. Entities acquired prior to that date were recognised in accordance with accounting principles prevailing at that time, taking into account the necessary corrections and adjustments at the transition date.
The Group applies the revised IFRS 3: Business Combinations in transactions made subsequent to 1 January 2010.
The Company applies the acquisition method for business combinations.
The acquisition date is the date on which the Company obtains control of the acquiree.

20

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Business combinations made subsequent to 1 January 2010
The consideration transferred in a business combination is determined at acquisition date and calculated as the sum of the fair values of the assets transferred, the liabilities incurred or assumed, the equity interests issued and any asset or liability contingent consideration depending on future events or the compliance of certain conditions in exchange for the control of the business acquired.
The consideration transferred excludes any payment that does not form part of the exchange for the acquired business. Acquisition-related costs are accounted for as expenses when incurred. Share increase costs are recognised as equity when the increase takes place and borrowing costs are deducted from the financial liability when it is recognised.
At the acquisition date the Group recognizes, at fair value, the assets acquired and liabilities assumed. Liabilities assumed include contingent liabilities provided that they represent present obligations that arise from past events and their fair value can be measured reliably. The Group also recognises indemnification assets transferred by the seller at the same time and following the same measurement criteria as the item that is subject to indemnification from the acquired business taking into consideration, where applicable, the insolvency risk and any contractual limit on the indemnity amount.
This criteria does not include non-current assets or disposable groups of assets which are classified as held for sale, long-term defined benefit employee benefit liabilities, share-based payment transactions, deferred tax assets and liabilities and intangible assets arising from the acquisition of previously transferred rights.
Assets and liabilities assumed are classified and designated for subsequent measurement in accordance with the contractual terms, economic conditions, operating or accounting policies and other factors that exist at the acquisition date, except for leases and insurance contracts.
The excess between the consideration transferred and the value of net assets acquired and liabilities assumed, less the value assigned to minority interests, is recognised as goodwill. Where the excess is negative, a bargain purchase gain is recognized immediately in profit and loss.
Any contingent consideration payable is recognized at fair value at the acquisition date. If the contingent consideration is classified as equity, it is not remeasured and settlement is accounted for within equity. Otherwise, subsequent changes to the fair value of the contingent consideration are recognized in profit and loss.

21

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Business combinations made prior to 1 January 2010
The cost of the business combination is calculated as the sum of the acquisition-date fair values of the assets transferred, the liabilities incurred or assumed, and equity instruments issued by the Group, in exchange for control of the acquiree, plus any costs directly attributable to the business combination. Any additional consideration contingent on future events or the fulfilment of certain conditions is included in the cost of the combination provided that it is probable that an outflow of resources embodying economic benefits will be required and the amount of the obligation can be reliably estimated. Subsequent recognition of contingent considerations or subsequent variations to contingent considerations are recognised as a prospective adjustment to the cost of the business combination.
Where the cost of the business combination exceeds the Group’s interest in the fair value of the identifiable net assets of the entity acquired, the difference is recognised as goodwill. If the acquirer’s interest in the fair value of net assets exceeds the cost of the business combination, the difference remaining after reassessment is recognised by the acquirer in profit and loss.
(c) Non-controlling interests
Prior to adoption of IFRS 3 (Revised) non-controlling interests in subsidiaries acquired after 1 January 2004 were recognised at the acquisition date at the proportional part of the fair value of the identifiable net assets. Non-controlling interests in subsidiaries acquired prior to the transition date were recognised at the proportional part of the equity of the subsidiaries at the date of first consolidation.
Non-controlling interests are disclosed in the consolidated balance sheet under equity separately from equity attributable to the parent. Non-controlling interests’ share in consolidated profit or loss for the year (and in consolidated comprehensive income for the year) is disclosed separately in the consolidated income statement (consolidated statement of comprehensive income).

22

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Consolidated comprehensive income and changes in equity of the subsidiaries attributable to the Group and non-controlling interests after consolidation adjustments and eliminations, is determined in accordance with the percentage ownership at year end, without considering the possible exercise or conversion of potential voting rights and after discounting the effect of dividends, agreed or otherwise, on preference shares with cumulative rights classified in equity accounts. However, Group and non-controlling interests are calculated taking into account the possible exercise of potential voting rights and other derivative financial instruments which, in substance, currently allow access to the economic benefits associated with the interests held, such as entitlement to a share in future dividends and changes in the value of subsidiaries.
The excess of losses attributable to non-controlling interests, which cannot be attributed to the latter as such losses exceed their interest in the equity of the Company, is recognised as a decrease in the equity of the Company, except when the non-controlling interests are obliged to assume part or all of the losses and are in a position to make the necessary additional investment. Subsequent profits obtained by the Group are attributed to the Company until the non-controlling interests’s share in prior years’ losses is recovered.
As of 1 January 2010 and in accordance with IFRS 3 (Revised), profit and loss and each component of other comprehensive income are assigned to equity attributable to shareholders of the Parent company and to non-controlling interests in proportion to their interest, although this implies a balance receivable from non-controlling interests. Agreements signed between the Group and the non-controlling interests are recognised as a separate transaction.
(d) Associates and joint ventures
Associates
Associates are entities over which the Company has significant direct or indirect influence through subsidiaries. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies. The existence of potential voting rights that are currently exercisable or convertible, including potential voting rights held by the Group or other entities, are considered when assessing whether an entity has significant influence.
Investments in associates are accounted for using the equity method from the date that significant influence commences until the date that significant influence ceases.
Details of investments accounted for using the equity method are included in note 2 (c).

23

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Purchases of shareholdings in associates are recognised applying the acquisition method, as described for subsidiaries. Any excess of cost of acquisition over the part of fair value of the identifiable net assets acquired is considered as goodwill, which is included in the fair value of the investment. If the cost of acquisition is less than the fair value of identifiable net assets acquired, the difference is recognised when determining the investor’s share in the profit of the associate in the period of acquisition.
The Group’s share in the profit or loss of the associates from the date of acquisition is recognised as an increase or decrease in the value of the investments, with a credit or debit to profit or loss of associates accounted for using the equity method of the consolidated income statement (consolidated statement of comprehensive income). The Group’s share in other comprehensive income of the associate obtained from the date of acquisition is recognised as an increase or decrease in the investment in the associate with a balancing entry on a separate line in other comprehensive income. The distribution of dividends is recognised as a decrease in the value of the investment. The Group’s share of profit and loss, including impairment losses recognised by the associates, is calculated based on income and expenses arising from application of the purchase method.
The Group’s share in the profit or loss of an associate and changes in equity are calculated to the extent of the Group’s interest in the associate at year end and does not reflect the possible exercise or conversion of potential voting rights. However, the Group’s share is calculated taking into account the possible exercise of potential voting rights and other derivative financial instruments which, in substance, currently allow access to the economic benefits associated with the interests held, such as entitlement to a share in future dividends and changes in the value of associates.
Losses of an associate attributable to the Group are limited to the extent of its interest, except where the Group has legal or implicit obligations or when payments have been made on behalf of the associate. For the purpose of recognising losses in associates, net investments are considered as the carrying amount of the investment after application of the equity method plus any other item which in substance forms part of the investment in the associate. Subsequent profits attributable to those associates for which impairment losses are limited are recognised to the extent of the previously unrecognised losses.
Unrealised gains and losses on transactions between the Group and associates are only recognised when they relate to interests of other unrelated investors, except in the case of unrealised losses evidencing the impairment of the transferred asset.
The accounting policies of associates have been harmonised in terms of timing and measurement, applying the policies described for subsidiaries.

24

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Joint ventures
Joint ventures are those in which there is a contractual agreement to share the control over an economic activity, in such a way that strategic financial and operating decisions relating to the activity require the unanimous consent of the Group and the remaining venturers.
Investments in joint ventures are accounted for using the equity method.
The acquisition cost of investments in joint ventures is determined consistently with that established for investments in associates.
(e) Foreign currency transactions
(i) Functional currency and presentation currency
The consolidated financial statements are presented in thousands of Euros, which is the functional and presentation currency of the Company.
(ii) Transactions, balances and cash flows in foreign currency
Foreign currency transactions are translated into the functional currency using the previous month’s exchange rate for all transactions performed during the current month. This method does not differ significantly from applying the exchange rate at the date of the transaction.
Monetary assets and liabilities denominated in foreign currencies have been translated into thousands of Euros at the closing rate, while non-monetary assets and liabilities measured at historical cost have been translated at the exchange rate prevailing at the transaction date. Non-monetary assets measured at fair value have been translated into thousands of Euros at the exchange rate at the date that the fair value was determined.
In the consolidated statement of cash flows, cash flows from foreign currency transactions have been translated into thousands of Euros at the exchange rates prevailing at the dates the cash flows occur. The effect of exchange rate fluctuations on cash and cash equivalents denominated in foreign currencies is recognised separately in the statement of cash flows as “Effect of exchange rate fluctuations on cash and cash equivalents”.

25

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Exchange gains and losses arising on the settlement of foreign currency transactions and the translation into thousands of Euros of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss.
(iii) Translation of foreign operations
The translation into thousands of Euros of foreign operations for which the functional currency is not the currency of a hyperinflationary economy is based on the following criteria:
• Assets and liabilities, including goodwill and net asset adjustments derived from the acquisition of the operations, including comparative amounts, are translated at the closing rate at each balance sheet date.
• Income and expenses, including comparative amounts, are translated into thousands of Euros using the previous month’s exchange rate for all transactions performed during the current month. This method does not differ significantly from using the exchange rate at the date of the transaction;
• All resulting exchange differences are recognised as translation differences in equity.
In the consolidated statement of cash flows, cash flows, including comparative balances, of the subsidiaries and foreign joint ventures are translated into thousands of Euros applying the exchange rates prevailing at the transaction date.
(f) Borrowing costs
In accordance with IAS 23: Borrowing Costs, since 1 January 2009 the Group recognises interest cost directly attributable to the purchase, construction or production of qualifying assets as an increase in the value of these assets. Qualifying assets are those which require a substantial period of time before they can be used or sold. To the extent that funds are borrowed specifically for the purpose of obtaining a qualifying asset, the amount of borrowing costs eligible for capitalisation is determined as the actual borrowing costs incurred, less any investment income on the temporary investment of those funds. Capitalised borrowing costs corresponding to general borrowing are calculated as the weighted average of the qualifying assets without considering specific funds. The amount of borrowing costs capitalised cannot exceed the amount of borrowing costs incurred during that period. The capitalised interest cost includes adjustments to the carrying amount of financial liabilities arising from the effective portion of hedges entered into by the Group.

26

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The Group begins capitalising borrowing costs as part of the cost of a qualifying asset when it incurs expenditures for the asset, interest is accrued, and it undertakes activities that are necessary to prepare the asset for its intended use or sale, and ceases capitalising borrowing costs when all or substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete. Nevertheless, capitalisation of borrowing costs is suspended when active development is interrupted for extended periods.
(g) Property, plant and equipment
(i) Initial recognition
Property, plant and equipment are recognised at cost or deemed cost, less accumulated depreciation and any accumulated impairment losses. The cost of self-constructed assets is determined using the same principles as for an acquired asset, while also considering the criteria applicable to production costs of inventories. Capitalised production costs are recognised by allocating the costs attributable to the asset to “self-constructed non-current assets” in the consolidated income statement.
At 1 January 2004, upon their first application of IFRS-EU, the Group opted to apply the exemption regarding fair value and revaluation as deemed cost as permitted by IFRS 1: First-time Adoption of IFRS.
(ii) Depreciation
Property, plant and equipment are depreciated by allocating the depreciable amount of an asset on a systematic basis over its useful life. The depreciable amount is the cost or deemed cost less its residual value. The Group determines the depreciation charge separately for each component of property, plant and equipment with a cost that is significant in relation to the total cost of the asset.
Depreciation of property, plant and equipment is determined based on the following criteria outlined belows:
Depreciation
method Rates
Buildings
Straight line 1% - 3%
Plant and machinery
Straight line 8%-10%
Other installations, equipment and furniture
Straight line 10% - 30%
Other property, plant and equipment
Straight line 16% - 25%

27

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The Group reviews residual values, useful lives and depreciation methods at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates.
(iii) Subsequent recognition
Subsequent to initial recognition of the asset, only those costs incurred which will probably generate future economic benefits and for which the amount may reliably be measured are capitalised. Costs of day-to-day servicing are recognised in profit and loss as incurred.
The Group recognises in the carrying amount of an item of property, plant and equipment the cost of replacing part of such an item when that cost is incurred if the recognition criteria are met. The carrying amount of those parts that are replaced is derecognised in accordance with the derecognition provisions of IAS 16.
(iv) Impairment
The Group tests for impairment and reversals of impairment losses on property, plant and equipment based on the criteria set out in section (i) of this note.
(h) Intangible assets
(i) Goodwill
Goodwill is generated on business combinations. As permitted by IFRS 1: First-time Adoption of International Financial Reporting Standards, the Group has recognised only business combinations that occurred on or after 1 January 2004, the date of transition to IFRS-EU, using the acquisition method. Entities acquired prior to that date were recognised in accordance with accounting principles prevailing at that time, taking into account the necessary corrections and adjustments at the transition date.
Goodwill is not amortised, but tested for impairment annually or more frequently if events indicate a potential impairment loss. Goodwill acquired in business combinations is allocated to the cash-generating units (CGUs) or groups of CGUs which are expected to benefit from the synergies of the business combination and the criteria described in note 7 are applied. After initial recognition, goodwill is measured at cost less any accumulated impairment losses.

28

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(ii) Internally generated intangible assets
Any research and development expenditure incurred during the research phase of projects is recognised as an expense when incurred.
Costs related with development activities are capitalised when:
• The Group has technical studies justifying the feasibility of the production process.
• The Group has undertaken a commitment to complete production of the asset whereby it is in condition for sale or internal use.
• The asset will generate sufficient future economic benefits.
• The Group has sufficient financial and technical resources to complete development of the asset and has developed budget and cost accounting control systems which allow budgeted costs, introduced changes and costs actually assigned to different projects to be monitored.
The cost of internally generated assets is calculated using the same criteria established for determining production costs of inventories. The production cost is capitalised by allocating the costs attributable to the asset to self-constructed assets in the consolidated income statement.
Costs incurred in the course of activities which contribute to increasing the value of the different businesses in which the Group as a whole operates are expensed as they are incurred. Replacements or subsequent costs incurred on intangible assets are generally recognised as an expense, except where they increase the future economic benefits expected to be generated by the assets.
(iii) Other intangible assets
Other intangible assets are carried at cost, less accumulated amortisation and impairment losses.

29

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(iv) Emission rights
Emission rights, which are recognised when the Group becomes entitled to such rights, are carried at cost less accumulated impairment. Rights acquired free of charge or at a price substantially lower than fair value, are recognised at fair value, which is generally the market value of the rights at the start of the calendar year. The difference between fair value and, where appropriate, the amount received, is recognised under “government grants”. Government grants are recognised in profit or loss in line with the emission of gases in proportion to total emissions foreseen for the complete period for which the emission rights have been received, irrespective of whether the rights previously received have been sold or impaired.
Under the terms of Law 1 of 9 March 2005 governing greenhouse gas emission rights, emission rights deriving from a certified reduction in emissions or from a unit created to reduce emissions through clean development mechanisms or a pooling of rights, are carried at cost of production using the same criteria as for inventories.
Emission rights are not amortised. The Group derecognises emission rights on a weighted average cost basis.
(v) Useful life and amortisation rates
The Group assesses whether the useful life of each intangible asset acquired is finite or indefinite. An intangible asset is regarded by the Group as having an indefinite useful life when there is no foreseeable limit to the period over which the asset will generate net cash inflows.
Intangible assets with indefinite useful lives are not amortised but tested for impairment at least annually.
Intangible assets with finite useful lives are amortised by allocating the depreciable amount of an asset on a systematic basis over its useful life, by applying the following criteria:
Amortisation Estimated years of
method useful life
Development expenses
Straight line 3 – 5
Concessions, patents, licences, trademarks and similar
Straight line 5 – 15
Software
Straight line 3 – 6
The depreciable amount is the cost or deemed cost of an asset less its residual value.

30

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The Group reviews the residual value, useful life and amortisation method for intangible assets at each financial year end. Changes to initially established criteria are accounted for as a change in accounting estimates.
(i) Impairment of non-financial assets subject to depreciation or amortisation
The Group evaluates whether there are indications of possible impairment losses on non-financial assets subject to amortisation or depreciation to verify whether the carrying amount of these assets exceeds the recoverable amount.
Irrespective of any indication of impairment, the Group tests for possible impairment of goodwill, intangible assets with indefinite useful lives, and intangible assets with finite useful lives not yet available for use, at least annually.
The recoverable amount is the higher of an asset’s fair value less costs to sell and its value in use. An asset’s value in use is calculated based on an estimate of the future cash flows expected to derive from the use of the asset, expectations about possible variations in the amount or timing of those future cash flows, the time value of money, the price for bearing the uncertainty inherent in the asset and other factors that market participants would reflect in pricing the future cash flows deriving from the asset.
Negative differences arising from comparison of the carrying amounts of the assets with their recoverable amounts are recognised in the consolidated income statement.
Recoverable amount is determined for each individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. If this is the case, recoverable amount is determined for the cash-generating unit (CGU) to which the asset belongs.
Impairment losses recognised for cash-generating units are first allocated to reduce, where applicable, the carrying amount of goodwill allocated to the CGU and then to the other assets of the CGU pro rata on the basis of the carrying amount of each asset. The carrying amount of each asset may not be reduced below the highest of its fair value less costs to sell, its value in use and zero.
At the end of each reporting period the Group assesses whether there is any indication that an impairment loss recognised in prior periods may no longer exist or may have decreased. Impairment losses on goodwill are not reversible. Impairment losses for other assets are only reversed if there has been a change in the estimates used to calculate the recoverable amount of the asset.

31

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
A reversal of an impairment loss is recognised in consolidated profit or loss. The increase in the carrying amount of an asset attributable to a reversal of an impairment loss may not exceed the carrying amount that would have been determined, net of depreciation or amortisation, had no impairment loss been recognised.
The reversal of an impairment loss for a CGU is allocated to its assets, except for goodwill, pro rata with the carrying amounts of those assets, with the limit per asset of the lower of its recoverable value and the carrying amount which would have been obtained, net of depreciation, had no impairment loss been recognised.
(j) Leases
(i) Lessee accounting records
The Group has the right to use certain assets through lease contracts.
Leases in which the Group assumes substantially all the risks and rewards incidental to ownership are classified as finance leases, otherwise they are classified as operating leases.
• Finance leases
At the commencement of the lease term, the Group recognises finance leases as assets and liabilities at the lower of the fair value of the leased asset and the present value of the minimum lease payments. Initial direct costs are added to the asset’s carrying amount. Minimum lease payments are apportioned between the finance charge and the reduction of the outstanding liability. The finance charge is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability. Contingent rents are recognised as an expense in the years in which they are incurred.
• Operating leases
Lease payments under an operating lease (excluding insurance and maintenance) are recognised as an expense on a straight-line basis unless another systematic basis is representative of the time pattern of the user’s benefit.

32

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(ii) Leasehold improvements
Non-current investments in properties leased from third parties are classified using the same criteria as for property, plant and equipment. Investments are amortised over the lower of their useful lives and the term of the lease contract. The lease term is consistent with that established for recognition of the lease.
(k) Financial instruments
(i) Classification of financial instruments
Financial instruments are classified on initial recognition as a financial asset, a financial liability or an equity instrument in accordance with the substance of the contractual arrangement and the definitions of a financial liability, a financial asset and an equity instrument set out in IAS 32: Financial Instruments — Presentation.
Financial instruments are classified into the following categories: financial assets and financial liabilities at fair value through profit and loss, loans and receivables, held-to-maturity investments, available-for-sale financial assets and financial liabilities. The Group classifies financial instruments into different categories based on the nature of the instruments and management’s intentions on initial recognition.
Regular way purchases and sales of financial assets are recognised at trade date, when the Group undertakes to purchase or sell the asset.
a) Financial assets at fair value through profit or loss
Financial assets and financial liabilities at fair value through profit or loss are those which are classified as held for trading or which the Group designated as such on initial recognition.
A financial asset or liability is classified as held for trading if:
• it is acquired or incurred principally for the purpose of selling or repurchasing it in the near term
• it forms part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent pattern of short-term profit-taking, or
• it is a derivative, except for a derivative which has been designated as a hedging instrument and complies with conditions for effectiveness or a derivative that is a financial guarantee contract.

33

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Financial assets and financial liabilities at fair value through profit or loss are initially recognised at fair value. Transaction costs directly attributable to the acquisition or issue are recognised as an expense.
The Group does not reclassify any financial assets or liabilities from or to this category while they are recognised in the consolidated balance sheet.
b) Loans and receivables
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, other than those classified in other financial asset categories. These assets are recognised initially at fair value, including transaction costs, and are subsequently measured at amortised cost using the effective interest method.
c) Available-for-sale financial assets
Available-for-sale financial assets are non-derivative financial assets that are either designated specifically to this category or do not comply with requirements for classification in the above categories.
Available-for-sale financial assets are initially recognised at fair value, plus any transaction costs directly attributable to the purchase.
After initial recognition, financial assets classified in this category are measured at fair value and any gain or loss is accounted for in other comprehensive income recognised in equity. On disposal of the financial assets, amounts recognised in other comprehensive income or the impairment losses are reclassified to profit or loss.
d) Financial assets and liabilities carried at cost
Investments in equity instruments whose fair value cannot be reliably measured and derivative instruments that are linked to and must be settled by delivery of such unquoted equity instruments, are measured at cost.
e) Financial assets and liabilities at fair value through profit or loss
Financial assets and financial liabilities at fair value through profit or loss, which comprise derivatives, are initially recognised at fair value and after initial recognition are recognised at fair value through profit and loss.

34

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(ii) Offsetting principles
A financial asset and a financial liability can only be offset when the Group currently has a legally enforceable right to set off the recognised amounts and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.
(iii) Fair value
The fair value is the amount for which an asset can be exchanged, or a liability settled, between knowledgeable, willing parties in an arm’s length transaction. The Group generally applies the following systematic hierarchy to determine the fair value of financial assets and financial liabilities:
• Firstly, the Group applies the quoted prices of the most advantageous active market to which the entity has immediate access, adjusted where appropriate to reflect any differences in counterparty credit risk between instruments traded in that market and the one being valued. The quoted market price for an asset held or liability to be issued is the current bid price and, for an asset to be acquired or liability held, the asking price. If the Group has assets and liabilities with offsetting market risks, it uses mid-market prices as a basis for establishing fair values for the offsetting risk positions and applies the bid or asking price to the net open position as appropriate.
• When current bid and asking prices are unavailable, the price of the most recent transactions is used, adjusted to reflect changes in economic circumstances.
• Otherwise, the Group applies generally accepted measurement techniques using, insofar as is possible, market data and, to a lesser extent, specific Group data.
(iv) Amortised cost
The amortised cost of a financial asset or liability is the amount at which the asset or liability was measured at initial recognition, minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and maturity amount and minus any reduction for impairment or uncollectibility.

35

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(v) Impairment of financial assets carried at cost
The amount of the impairment loss on assets carried at cost is measured as the difference between the carrying amount of the financial asset and the present value of estimated future cash flows discounted at the current market rate of return for a similar financial asset. Such impairment losses cannot be reversed and are therefore recognised directly against the value of the asset and not as an allowance account.
(vi) Impairment of available-for-sale financial assets
When a decline in the fair value of an available-for-sale financial asset at fair value through profit or loss has been accounted for in other comprehensive income, the accumulative loss is reclassified from equity to profit or loss when there is objective evidence that the asset is impaired, even though the financial asset has not been derecognised. The impairment loss recognised in profit and loss is calculated as the difference between the acquisition cost, net of any reimbursements or repayment of the principal, and the present fair value, less any impairment loss previously recognised in profit and loss for the year.
Impairment losses relating to investments in equity instruments are not reversible and are therefore recognised directly against the value of the asset and not as a corrective provision.
If the fair value of debt instruments increases and the increase can be objectively related to an event occurring after the impairment loss was recognised, the increase is recognised in profit and loss up to the amount of the previously recognised impairment loss and any excess is accounted for in other comprehensive income recognised in equity.
(vii) Financial liabilities
Financial liabilities, including trade and other payables, which are not classified at fair value through profit or loss, are initially recognised at fair value less any transaction costs that are directly attributable to the issue of the financial liability. After initial recognition, liabilities classified under this category are measured at amortised cost using the effective interest method.
(viii) Derecognition of financial assets
The Group applies the criteria for derecognition of financial assets to part of a financial asset or part of a group of similar financial assets or to a financial asset or group of similar financial assets.

36

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Financial assets are derecognised when the contractual rights to the cash flows from the financial asset expire or have been transferred and the Group has transferred substantially all the risks and rewards of ownership. Where the Group retains the contractual rights to receive cash flows, it only derecognises financial assets when it has assumed a contractual obligation to pay the cash flows to one or more recipients and if the following requirements are met:
• Payment of the cash flows is conditional on their prior collection.
• The Group is unable to sell or pledge the financial asset.
• The cash flows collected on behalf of the eventual recipients are remitted without material delay and the Group is not entitled to reinvest the cash flows. This criterion is not applicable to investments in cash or cash equivalents made by the Group during the settlement period from the collection date to the date of required remittance to the eventual recipients, provided that interest earned on such investments is passed on to the eventual recipients.
If the Group neither transfers nor retains substantially all the risks and rewards of ownership of the financial asset, it determines whether it has retained control of the financial asset. In this case:
• If the Group has not retained control, it derecognises the financial asset and recognises separately as assets or liabilities any rights and obligations created or retained in the transfer.
• If the Group has retained control, it continues to recognise the financial asset to the extent of its continuing involvement in the financial asset and recognises an associated liability. The extent of the Group’s continuing involvement in the transferred asset is the extent to which it is exposed to changes in the value of the transferred asset. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Group has retained. The associated liability is measured in such a way that the carrying amount of the transferred asset and the associated liability is equal to the amortised cost of the rights and obligations retained by the Group, if the transferred asset is measured at amortised cost, or to the fair value of the rights and obligations retained by the Group, if the transferred asset is measured at fair value. The Group continues to recognise any income arising on the transferred asset to the extent of its continuing involvement and recognises any expense incurred on the associated liability. Recognised changes in the fair value of the transferred asset and the associated liability are accounted for consistently with each other in profit and loss or equity, following the general recognition criteria described previously, and are not offset.

37

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
If the Group retains substantially all the risks and rewards of ownership of a transferred financial asset, the consideration received is recognised in equity. Transaction costs are recognised in profit and loss using the effective interest method.
(l) Hedge accounting
Hedging financial instruments are initially recognised using the same criteria as those described for financial assets and financial liabilities. Hedging financial instruments that do not meet the hedge accounting requirements are classified and measured as financial assets and financial liabilities at fair value through profit and loss. Derivative financial instruments which qualify for hedge accounting are initially measured at fair value.
At the inception of the hedge the Group formally designates and documents the hedging relationships and the objective and strategy for undertaking the hedges. Hedge accounting is only applicable when the hedge is expected to be highly effective at the inception of the hedge and in subsequent years in achieving offsetting changes in fair value or cash flows attributable to the hedged risk, throughout the period for which the hedge was designated (prospective analysis) and the actual effectiveness, which can be reliably measured, is within a range of 80%-125% (retrospective analysis).
Cash flow hedges
The Group recognises the portion of the gain or loss on the measurement at fair value of a hedging instrument that is determined to be an effective hedge in other comprehensive income. The ineffective portion and the specific component of the gain or loss or cash flows on the hedging instrument, excluding the measurement of the hedge effectiveness, are recognised with a debit or credit to finance expenses or finance income.
If a hedge of a forecast transaction subsequently results in the recognition of a financial asset or a financial liability, the associated gains or losses that were recognised in other comprehensive income are reclassified from equity to profit or loss in the same period or periods during which the asset acquired or liability assumed affects profit or loss and under the same caption of the consolidated income statement (consolidated statement of comprehensive income).
(m) Company own shares
The Group’s acquisition of equity instruments of the Company is recognised separately at cost of acquisition in the consolidated balance sheet as a reduction in equity, regardless of the motive of the purchase. Any gains or losses on transactions with own equity instruments are not recognised in consolidated profit or loss.

38

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The subsequent redemption of Company shares, where applicable, leads to a reduction in share capital in an amount equivalent to the par value of such shares. Any positive or negative difference between the cost of acquisition and the par value of the shares is debited or credited to accumulated gains.
Transaction costs related with own equity instruments, including the issue costs related with a business combination, are accounted for as a deduction from equity, net of any tax effect.
Transactions realized in instruments of the Company’s own equity are shown under equity and any gains or losses are also credited or debited against reserves.
(n) Inventories
Inventories are measured at the lower of cost and net realisable value. The cost of inventories comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition.
The costs of conversion of inventories include costs directly related to the units of production and a systematic allocation of fixed and variable production overheads that are incurred in converting. Fixed production overheads are allocated based on the higher of normal production capacity or actual level of production.
The cost of raw materials and other supplies, the cost of merchandise and costs of conversion are allocated to each inventory unit on a first-in, first-out (FIFO) basis.
The Group uses the same cost model for all inventories of the same nature and with a similar use within the Group.
Volume discounts extended by suppliers are recognised as a reduction in the cost of inventories when it is probable that the conditions for discounts to be received will be met. Discounts for prompt payment are recognised as a reduction in the cost of the inventories acquired.
The cost of inventories is adjusted against profit and loss when cost exceeds the net realisable value. Net realisable value is considered as follows:
• Raw materials and other supplies: replacement cost. Nevertheless, raw materials are not written down below cost if the finished goods into which they will be incorporated are expected to be sold at or above cost of production.
• Goods for resale and finished goods: estimated selling price, less costs to sell.

39

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
• Work in progress: the estimated selling price of related finished goods, less the estimated costs of completion and the estimated costs necessary to make the sale.
The previously recognised reduction in value is reversed against profit and loss when the circumstances that previously caused inventories to be written down no longer exist or when there is clear evidence of an increase in net realisable value because of changed economic circumstances. The reversal of the reduction in value is limited to the lower of the cost and revised net realisable value of the inventories. Write-downs may be reversed with a credit to inventories of finished goods and work in progress and supplies.
(o) Cash and cash equivalents
Cash and cash equivalents include cash on hand and demand deposits in financial institutions. They also include other short-term, highly liquid investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. An investment normally qualifies as a cash equivalent when it has a maturity of less than three months from the date of acquisition.
The Group classifies cash flows relating to interest received and paid as operating activities, and dividends received and distributed by the Company are classified under investing and financing activities, respectively.
(p) Government grants
Government grants are recognised in the balance sheet when there is reasonable assurance that they will be received and that the Group will comply with the conditions attached.
(i) Capital grants
Outright capital grants are initially recognised as deferred income in the consolidated balance sheet. Income from capital grants is recognised as other income in the consolidated income statement in line with the depreciation of the corresponding financed assets.
(ii) Operating grants
Operating grants received to offset expenses or losses already incurred, or to provide immediate financial support not related to future disbursements, are recognised as other income in the consolidated income statement.

40

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(iii) Interest rate grants
Financial liabilities comprising implicit assistance in the form of below market interest rates are initially recognised at fair value. The difference between this value, adjusted where necessary for the emission costs of the financial liability and the amount received, is recognised as an official grant based on the nature of the grant awarded.
(q) Employee benefits
(i) Defined contribution plans
The Group recognises the contributions payable to a defined contribution plan in exchange for a service in the period in which contributions are accrued. Accrued contributions are recognised as an employee benefit expense in the corresponding consolidated income statement in the year that the contribution was made.
(ii) Termination benefits
Termination benefits payable that do not relate to restructuring processes in progress are recognised when the Group is demonstrably committed to terminating the employment of current employees prior to retirement date. The Group is demonstrably committed to terminating the employment of current employees when a detailed formal plan has been prepared and there is no possibility of withdrawing or changing the decisions made.
(iii) Short-term employee benefits
The Group recognises the expected cost of short-term employee benefits in the form of accumulating compensated absences when the employees render service that increases their entitlement to future compensated absences. In the case of non-accumulating compensated absences, the expense is recognised when the absences occur.
The Group recognises the expected cost of profit-sharing and bonus payments when it has a present legal or constructive obligation to make such payments as a result of past events and a reliable estimate of the obligation can be made.
(r) Provisions
Provisions are recognised when the Group has a present obligation (legal or implicit) as a result of a past event; it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation; and a reliable estimate can be made of the amount of the obligation.

41

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation at the end of the reporting period, taking into account all risks and uncertainties surrounding the amount to be recognised as a provision and, where the time value of money is material, the financial effect of discounting provided that the expenditure to be made each period can be reliably estimated. The discount rate is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The discount rate does not reflect risks for which future cash flow estimates have been adjusted.
If it is no longer probable that an outflow of resources embodying economic benefits will be required to settle the obligation, the provision is reversed against the consolidated income statement item where the corresponding expense was recognised.
(s) Revenue recognition
Revenue is measured at the fair value of the consideration received or receivable for the sale of goods and services, net of VAT and any other amounts or taxes which are effectively collected on the behalf of third parties. Volume or other types of discounts for prompt payment are recognised as a reduction in revenues if considered probable at the time of revenue recognition.
(i) Sale of goods
The Group recognises revenue from the sale of goods when:
• the Group has transferred to the buyer the significant risks and rewards of ownership of the goods.
• the Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
• the amount of revenue can be measured reliably;
• it is probable that the economic benefits associated with the transaction will flow to the Group; and
• the costs incurred or to be incurred in respect of the transaction can be measured reliably.

42

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(ii) Rendering of services
Revenues associated with the rendering of service transactions are recognised by reference to the stage of completion at the consolidated balance sheet date when the outcome of the transaction can be estimated reliably, i.e., when revenues, the stage of completion, the costs incurred and the costs to complete the transaction can be estimated reliably and it is probable that the economic benefits derived from the transaction will flow to the Group.
When the outcome of the transaction involving the rendering of services cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.
(iii) Revenue from dividends
Revenue from dividends is recognised when the Group’s right to receive payment is established.
(iv) Revenue from interest on delayed collections
Under European legislation governing credit periods allowed by government entities (Social Security, in the case of the Group) to pay suppliers under government contracts, certain subsidiaries of the Group recover delay interest prescribed by legislation, after forward claims have been made in courts of law. To the extent that such delay interest claims are recognized by the courts and collected, the Group accrues interest on the basis of its historical experience.
(t) Income taxes
The income tax expense and tax income for the year comprises current tax and deferred tax.
Current tax is the amount of income taxes payable or recoverable in respect of the consolidated taxable profit or consolidated tax loss for the year. Current tax assets or liabilities are measured at the amount expected to be paid to or recovered from the taxation authorities, using the tax rates and tax laws that have been enacted or substantially enacted at the balance sheet date.

43

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Deferred tax liabilities are the amounts of income taxes payable in future periods in respect of taxable temporary differences, whereas deferred tax assets are the amounts of income taxes recoverable in future periods in respect of deductible temporary differences, the carryforward of unused tax losses, and the carryforward of unused tax credits. Temporary differences are differences between the carrying amount of an asset or liability in the balance sheet and its tax base.
Current and deferred tax are recognised as income or an expense and included in profit or loss for the year except to the extent that the tax arises from a transaction or event which is recognised, in the same or a different year, directly in equity, or a business combination.
(i) Taxable temporary differences
Taxable temporary differences are recognised in all cases except where:
• They arise from the initial recognition of goodwill or an asset or liability in a transaction which is not a business combination and at the time of the transaction, affects neither accounting profit nor taxable income;
• They are associated with investments in subsidiaries over which the Group is able to control the timing of the reversal of the temporary difference and it is not probable that the temporary difference will reverse in the foreseeable future.
(ii) Deductible temporary differences
Deductible temporary differences are recognised provided that:
• It is probable that taxable profit will be available against which the deductible temporary difference can be utilised, unless the differences arise from the initial recognition of an asset or liability in a transaction which is not a business combination and at the time of the transaction, affects neither accounting profit nor taxable profit.
• The temporary differences are associated with investments in subsidiaries to the extent that the difference will reverse in the foreseeable future and sufficient taxable income is expected to be generated against which the temporary difference can be offset.
Tax planning opportunities are only considered on evaluation of the recoverability of deferred tax assets and if the Group intends to use these opportunities or it is probable that they will be utilised.

44

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(iii) Measurement
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply to the years when the asset is realised or the liability is settled, based on tax rates and tax laws that have been enacted or substantively enacted. The tax consequences that would follow from the manner in which the Group expects to recover or settle the carrying amount of its assets or liabilities are also reflected in the measurement of deferred tax assets and liabilities.
At year end the Group reviews the carrying amount of deferred tax assets to write down the balance if it is not probable that sufficient taxable income will be available to apply the tax asset.
Deferred tax assets which do not meet the above conditions are not recognised in the consolidated balance sheet. At year end the Group assesses whether deferred tax assets which were previously not recognised currently meet the conditions for recognition.
(iv) Offset and recognition
The Group only offsets current tax assets and current tax liabilities if it has a legally enforceable right to set off the recognised amounts and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.
The Group only offsets deferred tax assets and liabilities where it has a legally enforceable right, where these relate to income taxes levied by the same taxation authority and where the taxation authority permits the entity to settle on a net basis, or to realise the asset and settle the liability simultaneously for each of the future years in which significant amounts of deferred tax assets or liabilities are expected to be settled or recovered.
Deferred tax assets and liabilities are recognised in the consolidated balance sheet under non-current assets or liabilities, irrespective of the expected date of recovery or settlement.
(u) Segment reporting
An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incur expenses, whose operating results are regularly reviewed by the Group’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and for which discrete financial information is available.

45

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(v) Classification of assets and liabilities as current and non-current
The Group classifies assets and liabilities in the consolidated balance sheet as current and non-current. Current assets and liabilities are determined as follows:
• Assets are classified as current when they are expected to be realised, or are intended for sale or consumption in the Group’s normal operating cycle within twelve months after the balance sheet date and they are held primarily for the purpose of trading. Cash and cash equivalents are also classified as current, except where they may not be exchanged or used to settle a liability, at least within twelve months after the balance sheet date.
• Liabilities are classified as current when they are expected to be settled in the Group’s normal operating cycle within 12 months after the balance sheet date and they are held primarily for the purpose of trading, or where the Group does not have an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.
• Financial liabilities are classified as current when they are due to be settled within twelve months after the reporting period, even if the original term was for a period longer than twelve months, and an agreement to refinance, or to reschedule payments, on a long-term basis is completed after the reporting period and before the consolidated financial statements are authorised for issue.
(5) Financial Risk Management Policy
(a) General
The Group is exposed to the following risks associated with the use of financial instruments:
• Credit risk
• Liquidity risk
• Market risk
This note provides information on the Group’s exposure to each of these risks, the Group’s objectives and procedures to measure and mitigate this risk, and the Group’s capital management strategy. More exhaustive quantitative information is disclosed in note 32.

46

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The Group’s risk management policies are established in order to identify and analyse the risks to which the Group is exposed, establish suitable risk limits and controls, and control risks and compliance with limits. Risk management procedures and policies are regularly reviewed to ensure they take into account changes in market conditions and in the Group’s activities. The Group’s management procedures and rules are designed to create a strict and constructive control environment in which all employees understand their duties and obligations.
The Group’s Audit Committee supervises how management controls compliance with the Group’s risk management procedures and policies and reviews whether the risk management policy is suitable considering the risks to which the Group is exposed. This committee is assisted by Internal Audit which acts as supervisor. Internal Audit performs regular and ad hoc reviews of the risk management controls and procedures and reports its findings to the Audit Committee.
Credit risk
Credit risk is the risk to which the Group is exposed in the event that a customer or counterparty to a financial instrument fails to discharge a contractual obligation, and mainly results from trade receivables and the Group’s investments in financial assets.
Trade receivables
The Group is not exposed to significant credit risk because most of the customers belong to the public healthcare system. The risk to which receivables from these entities are exposed is a risk of delays in payment. Group companies mitigate this risk by exercising their right to receive legal interest.
Furthermore, no significant bad debt issues have been detected in the markets in which it sells to private entities.
In the US market, the Group sells the majority of its products to distributors who in turn sell them to retail pharmacies, hospitals, homecare companies, and other health care facilities. Prices and quantities are contracted between the Group and the dispensing entities, either individually or through Group Purchase Organizations (GPOs). Group Purchasing Organizations are buying alliances of large numbers of hospitals and allied organizations that deliver cost-savings and efficiency benefits by leveraging their combined purchasing power. Other channels of distribution are primarily focused on sales directly to specialty pharmacies, haemophilia treatment centres and government entities. No significant bad debt issues have been detected with the customers the Group sells to.

47

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
The Group recognises valuation adjustments for impairment equivalent to its best estimate of the losses incurred in relation to trade and other receivables. The main valuation adjustments made are based on specific losses related with identified risks that are individually significant, while the bad debt risk in the Group is low because a significant proportion of receivables are due from public entities.
Financial instruments and deposits
The Group has invested part of the resources generated by the issue of bonds in the United States in deposits with financial institutions with sound credit ratings.
Liquidity risk
Liquidity risk is the risk that the Group cannot meet its financial obligations as they fall due. The Group’s approach to managing liquidity is to ensure where possible, that it always has sufficient liquidity to settle its obligations at the maturity date, both in normal conditions and in times of tension, to avoid incurring unacceptable losses or tarnishing the Group’s reputation.
The Group ensures the availability of financing through a sufficient amount of committed credit facilities to meet its payment obligations at due dates.
The Group issued bonds in the United States during 2009. The resources generated will enable the Group to extend the life of its debt from current to non-current and ensure that the necessary financial resources are available to implement its future plans. The resources generated have therefore been used to pay current and non-current liabilities, with the remaining amount, totalling Euros 211,539 thousand recognised as a current investment under “Cash and cash equivalents” at 31 December 2010 (Euros 237,777 thousand at 31 December 2009) (see note 22).
In the balance sheet at 31 December 2010, 22% of the financial liabilities is current and 78% non-current, while at 31 December 2009, 14% was current and 86% non-current.
Market risk
Market risk comprises the risk of changes in market prices, for example, exchange rates, interest rates, or the prices of equity instruments affecting the Group’s revenues or the value of financial instruments it holds. The objective of managing market risk is to manage and control the Group’s exposure to this risk within reasonable parameters at the same time as optimising returns.

48

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(i) Currency risk
The Group operates internationally and is therefore exposed to currency risks when operating with foreign currencies, especially with regard to the US Dollar. Currency risk is associated with future commercial transactions, recognised assets and liabilities, and net investments in foreign operations.
The Group holds several investments in foreign operations, the net assets of which are exposed to currency risk. Currency risk affecting net assets of the Group’s foreign operations in US Dollars are mitigated primarily through borrowings in the corresponding foreign currencies.
The Group’s main exposure to currency risk is due to the US Dollar, which is used in a significant percentage of transactions in foreign currencies. Since the Company had US Dollar revenues that were, as a proportion, 96.9% of US Dollar expenses during 2010, the Group has a natural hedge against US Dollar fluctuations and therefore the risks associated with such exchange-rate fluctuations are minimal.
Details of the Group’s exposure to currency risk at 31 December 2010, 2009 and 2008 of principal financial instruments are shown in note 32.
(ii) Interest-rate risk
The Group’s interest rate risks arise from current and non-current borrowings. Borrowings at variable interest rates expose the Group to cash flow interest rate risks. During 2010 and because of the issue of bonds in 2009 (see note 22 (a.1.1)), a significant portion of liabilities bear fixed interest rates, whereas the rest of the financial liabilities with banks bear variable interest rates. Nevertheless, the Group has a variable to fixed interest-rate swap for loans of Euros 50,000 thousand maturing in 2013 (see note 32).
(iii) Market price risk
The Group has signed two unquoted futures contracts, the underlying asset of which is shares in Grifols, S.A. It is therefore exposed to risk of value fluctuations.
Price risk affecting raw materials is mitigated by the vertical integration of the haemoderivatives business in a sector which is highly concentrated.

49

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
(b) Capital management
The directors’ policy is to maintain a solid capital base in order to ensure investor, creditor and market confidence and sustain future business development. The directors control capital performance using rates of returns on equity (ROE) and returns on invested capital (ROIC). The board of directors also controls the level of dividends paid to shareholders.
In 2010, the ROE stood at 16.7% (26.1% in December 2009 and 25.3% in December 2008) and the ROIC at 11.2% (13.9% in December 2009 and 15.3% in December 2008). The ROE is calculated by dividing profit attributable to the Company by the equity attributable to the Company. The ROIC is calculated by dividing operating profit after income tax by invested capital, which is equal to total assets less cash, less other current financial assets and less current and non-current financial liabilities excluding current and non-current borrowings.
Compared with these rates, the weighted average finance expense for interest-bearing liabilities (excluding liabilities with implicit interest) has been 4.8% in 2010 (3.9% in 2009 and 5.2% in 2008). Considering the September 2009 issue of bonds in the USA, the weighted average finance expense for interest-bearing liabilities for the fourth quarter of 2009 was 5.1%.
The Group has no share-based payment schemes for employees.
At 31 December 2010 the Group holds own shares equivalent to 0.07% of its share capital (0.03% at 31 December 2009). The Group does not have a formal plan for repurchasing shares.
(6) Segment Reporting
In accordance with IFRS 8: Operating Segments, financial information for operating segments is reported in the accompanying Appendix I, which forms an integral part of this note to the consolidated financial statements.
Group companies are divided into three areas: companies from the industrial area, companies from the commercial area and companies from the services area. Within each of these areas, activities are organised based on the nature of the products and services manufactured and marketed.

50

GRIFOLS, S.A. AND SUBSIDIARIES

Notes to the Consolidated Financial Statements
Assets, liabilities, income and expenses for segments include directly and reliably attributable items. Items which are not attributed to segments by the Group are:
• Balance sheet: cash and cash equivalents, receivables, public entities, deferred tax assets and liabilities, loans and borrowings and certain payables.
• Income statement: general administration expenses, other operating income / expenses, finance income / expense and income tax.
There have been no inter-segment sales.
(a) Operating segments
The operating segments defined by the Group are as follows:
• Bioscience: including all activities related with products deriving from human plasma for therapeutic use.
• Hospital: comprising all non-biological pharmaceutical products and medical supplies manufactured by Group companies earmarked for hospital pharmacy. Products related with this business which the Group does not manufacture but markets as supplementary to its own products are also included.
• Diagnostic: including the marketing of diagnostic testing equipment, reagents and other equipment, manufactured by Group or other companies.
• Raw materials: including sales of intermediate biological products and the rendering of manufacturing services to third party companies.
Details of net sales by groups of products for 2010, 2009 and 2008 as a percentage of net sales are as follows:
% of sales
2010 2009 2008
Hemoderivatives
77.9 % 76.0 % 75.6 %
Other hemoderivatives
0.2 % 0.2 % 0.3 %
Transfusional medicine
7.9 % 8.2 % 7.3 %
In vitro diagnosis
3.1 % 3.1 % 3.2 %
Fluid therapy and nutrition
5.0 % 5.2 % 5.7 %
Hospital supplies
4.1 % 4.2 % 4.4 %
Raw materials
0.5 % 2.5 % 2.8 %
Other
1.3 % 0.6 % 0.7 %
100 % 100 % 100 %

51

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(b) Geographical information
Geographical information is grouped into four areas:
• Spain
• Rest of the European Union
• United States of America
• Rest of the world
The financial information reported for geographical areas is based on sales to third parties in these markets as well as the location of assets.
(c) Main customer
No entity represents 10% or more of the Group’s sales.
(7) Goodwill
Details of and movement in goodwill in the year 2008 are as follows:
Thousands of Euros
Balances at Business Translation Balances at
31/12/07 combinations differences 31/12/08
Net value
Grifols UK,Ltd.
9,369 — (2,156 ) 7,213
Grifols Italia,S.p.A.
6,118 — — 6,118
Biomat USA, Inc.
85,390 2,372 5,256 93,018
Plasmacare, Inc.
34,912 — 2,017 36,929
Plasma Collection Centers, Inc.
14,454 — 835 15,289
150,243 2,372 5,952 158,567
(note 3(a ))

52

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Details of and movement in goodwill in the year 2009 are as follows:
Thousands of Euros
Balances at Business Translation Balances at
31/12/08 combinations differences 31/12/09
Net value
Grifols UK,Ltd.
7,213 — 523 7,736
Grifols Italia,S.p.A.
6,118 — — 6,118
Biomat USA, Inc.
93,018 225 (3,154 ) 90,089
Plasmacare, Inc.
36,929 — (1,253 ) 35,676
Plasma Collection Centers, Inc.
15.289 — (519 ) 14,770
Woolloomooloo Holdings Pty Ltd.
— 16,190 3,421 19,611
158,567 16,415 (982 ) 174,000
(note 3(a) and
3(b))
Details of and movement in goodwill in the year 2010 are as follows:
Thousands of Euros
Balances at Translation Balances at
31/12/09 Transfers differences 31/12/10
Net value
Grifols UK,Ltd.
7,736 — 246 7,982
Grifols Italia,S.p.A.
6,118 — — 6,118
Biomat USA, Inc.
90,089 14,770 8,193 113,052
Plasmacare, Inc.
35,676 — 2,788 38,464
Plasma Collection Centers, Inc.
14,770 (14,770 ) — —
Woolloomooloo Holdings Pty Ltd.
19,611 — 4,221 23,832
174,000 — 15,448 189,448
Impairment testing:
Goodwill has been allocated to each of the Group’s cash-generating units (CGUs) in accordance with their respective business segments and on a geographical basis, this being the lowest level at which goodwill is controlled by management for management purposes and lower than the operating segments. Plasma Collection Centers, Inc. and Plasmacare, Inc. are integrated into the management of Biomat USA, Inc. for the purpose of impairment analysis.

53

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Goodwill has been allocated to the cash generating units as follows:
- UK: bioscience segment
- Italy: bioscience segment
- USA: bioscience segment
- Australia: mainly to the Diagnostics segment.
The recoverable amount of a CGU is determined based on its value in use. These calculations are based on cash flow projections from the financial budgets approved by management. Cash flows estimated as of the year in which stable growth in the CGU has been reached are extrapolated using the estimated growth rates indicated below.
The key assumptions used in calculating value in use of the CGUs have been as follows:
Growth rate Discount rate after tax
2010 2009 2010 2009
Bioscience
2% - 3 % 3 % 8% - 8.5 % 8 %
Diagnostic
2 % 2 % 8.30 % 8.7 %
Management determines budgeted gross margins based on past experience and forecast market development. Average weighted growth rates are coherent with the forecasts included in industry reports. The discount rates used reflect specific risks related to the CGUs.
Paragraph A20 of IAS 36 requires the discount rate used to be a pre-tax rate and establishes that when the basis used to estimate the discount rate is post-tax, that basis is adjusted to reflect a pre-tax rate. The following pre-tax discount rates have been used:
Discount rate before tax
2010 2009
Bioscience
10.5% - 10.9 % 9.5% - 13 %
Diagnostic
10.40 % 9.8 %
The use of post-tax discount rates adjusted to reflect pre-tax discount rates has not given rise to any values in use which differ significantly from those which would have arisen had the discount rates been pre-tax.

54

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(8) Other Intangible Assets
Details of other intangible assets and movement during the years ended 31 December 2010, 2009 and 2008 are included in Appendix II, which forms an integral part of these notes to the consolidated financial statements.
The cost of fully-amortised intangible assets in use at 31 December 2010 and 2009 is Euros 57,203 thousand and Euros 38,183 thousand, respectively.
The Group has recognised Euros 9,963 thousand in 2010 (Euros 11,823 thousand in 2009 and Euros 7,644 thousand in 2008) as self-constructed assets.
At 31 December 2010 the Group has recognised licenses with indefinite useful lives under intangible assets for a carrying amount of Euros 24,691 thousand (Euros 23,379 thousand at 31 December 2009). The Group has also recognised Euros 11,492 thousand as costs of development in progress (Euros 21,943 thousand at 31 December 2009).
At 31 December 2010 the Group has recognised CO2 emission rights for Euros 534 thousand (Euros 493 thousand at 31 December 2009) (see note 4(h (iv))).
During 2010 the Group signed a distribution agreement for a new blood genotype test developed by Progenika Biopharma, acquiring a customer portfolio of Euros 1,358 thousand and which is recognised under “Other intangible assets”.
Impairment testing:
Indefinite-lived intangible assets have been allocated to the Group’s Plasmacare, Inc. and Biomat USA, Inc. cash-generating units (CGUs), which belong to the Bioscience segment.
The recoverable amount of a CGU is determined based on its value in use. These calculations are based on cash flow projections from the financial budgets approved by management. Cash flows estimated as of the year in which stable growth in the CGU has been reached are extrapolated using the estimated growth rates indicated below.
The key assumptions used in calculating value in use are as follows:
Discount rate after tax
2010 2009
Growth rate used to extrapolate projections
3 % 3 %
Discount rate after tax
8.5 % 8 %

55

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Paragraph A20 of IAS 36 requires the discount rate used to be a pre-tax rate and establishes that when the basis used to estimate the discount rate is post-tax, that basis is adjusted to reflect a pre-tax rate. The pre-tax rate in 2010 is 10.9% (9.5% in 2009). The use of a post-tax discount rate adjusted to reflect the pre-tax discount rate has not given rise to any values in use which differ significantly from those which would have arisen had the discount rates been pre-tax.
(9) Property, Plant and Equipment
Details of property, plant and equipment and movement in the consolidated balance sheet at 31 December 2010, 2009 and 2008 are included in Appendix III, which forms an integral part of these notes to the consolidated financial statements.
The main investments during the years 2010 and 2009 correspond to the construction of the production plants in Los Angeles and Parets del Vallès.
The main investments during the year 2008 have been as follows:
- Purchase of land and buildings in Parets del Vallès, Barcelona with a value of Euros 19.4 million, financed through a mortgage loan from Caixa Catalunya.
- Purchase of land and buildings under construction in Sant Cugat del Vallès, Barcelona through the acquisition of the real estate company Arrahona Optimus, S.L. for Euros 33 million at 31 December 2008, financed through a mortgage loan from BBVA.
Property, plant and development under construction at 31 December 2010 and 2009 mainly comprises investments made to extend the companies’ installations and to increase their productive capacity.
a) Mortgaged property, plant and equipment
At 31 December 2010 certain land and buildings have been mortgaged for Euros 49,316 thousand (Euros 45,382 thousand at 31 December 2009) to secure payment of certain loans (see note 22).
b) Official capital grants received
During 2010, the Group has received capital grants totalling Euros 323 thousand (Euros 742 thousand at 31 December 2009) (see note 20).

56

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
c) Insurance
Group policy is to contract sufficient insurance coverage for the risk of damage to property, plant and equipment. At 31 December 2010 and 2009 the Group has a combined insurance policy for all Group companies, which adequately covers the carrying amount of all the Group’s assets.
d) Revalued assets
At 1 January 2004, date of first adopting IFRS-EU, the Group opted to apply the exemption regarding fair value and revaluation as deemed cost as permitted by IFRS 1: First-time Adoption of IFRS. In accordance with this exemption, the Group’s land and buildings were revalued based on independent expert appraisals at 1 January 2004. Appraisals were performed based on market values.
e) Assets under finance lease
The Group had contracted the following types of property, plant and equipment under finance leases at 31 December 2009:
Thousands of Euros
Accumulated
Asset Cost depreciation Net value
Technical installations and other property, plant and equipment
19,641 (5,507 ) 14,134
The Group has contracted the following types of property, plant and equipment under finance leases at 31 December 2010:
Thousands of Euros
Accumulated
Asset Cost depreciation Net value
Technical installations and other property, plant and equipment
15,264 (4,782 ) 10,482
Details of minimum lease payments and the present value of finance lease liabilities, disclosed by maturity date, are detailed in note 22 (a.1.3).

57

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
f) Fully-depreciated assets
The cost of fully-depreciated property, plant and equipment in use at 31 December 2010 and 2009 is Euros 98,978 thousand and Euros 73,370 thousand, respectively.
g) Self-constructed property, plant and equipment
At 31 December 2010 the Group has recognised Euros 23,550 thousand as self-constructed property, plant and equipment (Euros 29,319 thousand at 31 December 2009 and Euros 18,150 thousand at 31 December 2008).
h) Purchase commitments
At 31 December 2010 the Group has property, plant and equipment purchase commitments amounting to Euros 6,148 thousand.
(10) Investments Accounted for Using the Equity Method
At 31 December 2009 and 2008 equity accounted investments comprised the investment held by Diagnostic Grifols, S.A. in the company Quest International, Inc. This company is located in Miami, Florida (USA) and its activity consists of the manufacture and commercialisation of reagents and clinical analysis instruments. On 9 November 2010 the Group sold its interest in the company for a sale price of Euros 621 thousand.
Because the Group had significant influence over these companies, the consolidation method used was the equity method.
Details of and movement in this caption in year 2008 are as follows:
Thousands of Euros
Balances at Translation Balances at
31/12/07 Gains differences 31/12/08
Equity accounted investments
243 24 107 374
Details of and movement in this caption in year 2009 are as follows:
Thousands of Euros
Balances at Translation Balances at
31/12/08 Gains differences 31/12/09
Equity accounted investments
374 51 (42 ) 383

58

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Details of and movement in this caption in year 2010 are as follows:
Thousands of Euros
Gain / (losses
Balances at & Translation Balances at
31/12/09 impairment) Disposals Acquisitions differences 31/12/10
Equity accounted investments
383 (879 ) (463 ) 1,472 85 598
The balance at 31 December 2010 relates to the investment (acquired in 2010) which Gri-cel, S.A. holds in Nanotherapix, S.L. (see note 2 (c), a joint venture which has been accounted for using the equity method).
Summarised financial information on the equity accounted investments is as follows:
Thousands of Euros
Percentage
Country ownership Assets Liabilities Equity Result
31/12/2008
Quest International, Inc
USA 35 % 1,736 667 1,069 69
31/12/2009
Quest International, Inc
USA 35 % 1,664 580 1,084 145
31/12/2010
Nanotherapix, S.L.
Spain 51 % 2,375 1,212 1,163 (312 )
(11) Non-Current Financial Assets
Details of this caption of the consolidated balance sheet at 31 December 2010, 2009 and 2008 are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Non-current guarantee deposits
1,217 1,142 1,113
Assets available for sale
535 501 523
Loans to third parties
5,783 2,088 —
Non-current financial assets
7,535 3,731 1,636

59

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
During 2010, the Group has extended two new mortgage loans totalling Euros 3,723 thousand to the owners of two plasma centres in the USA occupied by group companies. These loans have a term of 20 years, bear interest at a fixed rate of 4.5% and are secured by the property and by a personal security. This interest rate does not differ from a mortgage market interest rate. In 2009 the Group extended a similar mortgage loan for an amount of Euros 2,174 thousand.
At 31 December 2010, available-for-sale assets relate to the following:
- The interest of less than 1% that the Group holds in Northfield Laboratories, Inc. (USA). At 31 December 2010, 2009 and 2008 provision has been made for the full amount of this investment, based on its fair value.
- The interest of less than 2% in the share capital of biotechnology company, Cardio 3 Bioscience (with registered offices in Belgium) acquired by Grifols, S.A. in December 2008 for an amount of Euros 500 thousand. The activity of this company involves research into and the development of biological therapies using stem cells for the treatment of cardiovascular diseases. The Group has measured this asset at cost, as its fair value cannot be reliably determined.
(12) Inventories
Details of inventories at 31 December are as follows:
Thousands of Euros
2010 2009
Goods for resale
63,050 65,718
Raw materials and other supplies
160,326 170,987
Work in progress and semi-finished goods
203,971 146,612
Finished goods
100,518 101,145
527,865 484,462

60

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Movement in inventories of finished products, work in progress and materials consumed was as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
* * *
Inventories of goods for resale
Net purchases
56,542 50,886 79,902
Changes in inventories
6,911 (9,201 ) (22,700 )
63,453 41,685 57,202
Raw materials and supplies
Net purchases
225,994 274,537 190,667
Changes in inventories
17,412 (29,948 ) (41,131 )
243,406 244,589 149,536
Materials consumed
306,859 286,274 206,738
Changes in inventories of finished products and work in progress
(45,749 ) (73,093 ) (31,058 )
Changes in inventories of finished products , work in progress and materials consumed
261,110 213,181 175,680
* Expenses/(Income)
Reconciliation of goods for resale during 2010, 2009 and 2008 has been as follows:
Thousands of Euros
2010 2009 2008
Inventories of goods for resale at 1 January
65,718 54,509 37,138
Business combinations
— 158 —
Net cancellations for the year
— (568 ) (515 )
Increase / (decrease) of goods for resale
(6,911 ) 9,201 22,700
Translation differences
4,243 2,418 (4,814 )
Inventories of goods for resale at 31 December
63,050 65,718 54,509

61

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Reconciliation of inventories of raw materials and materials consumed during 2010, 2009 and 2008 has been as follows:
Thousands of Euros
2010 2009 2008
Inventories of raw materials at 1 January
170,987 142,209 96,044
Business combinations
— 824 —
Increase / (decrease) in raw materials
(17,412 ) 29,948 41,131
Translation differences
6,751 (1,994 ) 5,034
Inventories of raw materials at 31 December
160,326 170,987 142,209
Reconciliation of inventories of finished goods and work in progress during 2010, 2009 and 2008 has been as follows:
Thousands of Euros
2010 2009 2008
Inventories of finished goods and work in progress at 1 January
247,757 176,939 138,226
Business combinations
— 2,567 —
Increase in inventories of finished goods and work in progress
45,749 73,093 31,058
Translation differences
10,983 (4,842 ) 7.655
Inventories of finished goods and work in progress at 31 December
304,489 247,757 176,939
Net purchases include purchases made in the following foreign currencies:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Currency
US Dollar
145,584 196,936 168,037
Other currencies
6,569 4,498 7,315

62

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(13) Trade and Other Receivables
Details at 31 December 2010 and 2009 are as follows:
Thousands of Euros
31/12/10 31/12/09
Trade receivables
224,355 207,840
Other receivables
31,012 27,210
Associates
5 812
Personnel
366 395
Advances for fixed assets
494 1,103
Other advances
3,265 1,844
Public entities, other receivables
8,890 8,176
Other receivables
44,032 39,540
Current income tax assets
14,607 7,802
282,994 255,182
Trade receivables
Trade receivables, net of the provision for bad debts, include notes receivable discounted at banks at 31 December 2010, which amount to Euros 1,396 thousand (Euros 1,298 thousand at 31 December 2009) (see note 22).
Trade receivables include balances in the following foreign currencies:
Thousands of Euros
31/12/10 31/12/09
Currency
US Dollar
52,466 45,297
Chilean Peso
17,008 12,778
Mexican Peso
10,583 7,986
Argentinean Peso
4,075 3,404
Brazilian Real
4,616 3,225
Czech Crown
3,030 3,217
Pound Sterling
3,116 2,849
Thai Baht
1,842 1,366
Polish Zloty
2,379 1,292
Australian Dollar
3,769 1,101
Other currencies
2,412 1,644

63

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Other receivables
Other receivables at 31 December 2010 and 2009 include Euros 6,639 thousand (Euros 8,089 thousand at 31 December 2009) reflecting interest receivable from social security-affiliated entities.
During 2010, 2009 and 2008 certain Grifols Group companies have sold receivables without recourse from several public entities to Deutsche Bank, S.A.E. According to these contracts, the Group receives an initial payment which usually amounts to approximately 90% of the nominal amount of the receivables. Receipt of the deferred amount (remainder of the nominal amount) is collected by the Group once Deutsche Bank has collected the nominal amount of the receivables and until then the pending amount is recognised in the balance sheet as a receivable. Because the receivables are with public entities it is considered that there is very low credit risk. At 31 December 2010, Euros 19,504 thousand is receivable for this deferred amount (Euros 13,675 thousand at 31 December 2009). Initial payment is made when the sale is completed and therefore, the bad debt risk associated with this part of the nominal amount of the receivables is transferred. The Group has transferred control of the receivables to Deutsche Bank and therefore, the Group has derecognised the total initial payment on its balance sheet, since all risks and rewards have been transferred.
Certain foreign group companies and one Spanish company have also entered into contracts to sell receivables without recourse to financial institutions.
Total balances receivable without recourse sold to financial institutions through the aforementioned contracts amount to Euros 185.2 million at 31 December 2010 (Euros 116.3 million at 31 December 2009).
The finance cost of these operations for the Group totals approximately Euros 5,378 thousand which has been recognised under finance costs in the 2010 consolidated income statement (Euros 2,531 thousand in 2009 and Euros 2,128 thousand in 2008) (see note 28).
Details of balances with related parties are shown in note 33.
Receivables from public entities are as follows:
Thousands of Euros
31/12/10 31/12/09
Taxation authorities, VAT
8,191 7,451
Social Security
85 107
Other public entities
614 618
Public entities, other receivables
8,890 8,176

64

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Current tax assets
Current tax assets are as follows:
Thousands of Euros
31/12/10 31/12/09
Recoverable income tax:
Current year
9,352 7,188
Prior years
5,255 614
Current tax assets
14,607 7,802
(14) Other Current Financial Assets
Details of this caption of the consolidated balance sheet at 31 December 2010 and 2009 are as follows:
Thousands of Euros
31/12/10 31/12/09
Current investments
12,387 5,943
Guarantee deposits
44 209
Current loans to third parties
515 395
Financial derivatives (note 32)
— 1,670
Total other current financial assets
12,946 8,217
“Current investments” comprise current guarantee deposits held in financial institutions with maturity greater than three months from the date of acquisition.

65

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(15) Other Current Assets
Details of this caption of the consolidated balance sheet at 31 December 2010 and 2009 are as follows:
Thousands of Euros
31/12/10 31/12/09
Prepaid expenses — professional services
72,983 1,703
Prepaid expenses — insurance
3,508 3,403
Royalties and rentals
2,589 611
Other prepaid expenses
1,548 1,628
Total other current assets
80,628 7,345
At 31 December 2010 professional services include an amount of Euros 71,174 thousand relating to costs incurred for professional services directly relating to the share capital increase and the debt issue expected to be made in relation to the acquisition of Talecris (see note 31 (f)).
Costs related to the capital increase will be taken to equity when the capital increase is performed. Costs relating to the issue of debt will be deducted from the financial liability when it is recognised.
Costs incurred in relation to the business combination, amounting to Euros 16,999 thousand, have been recognised as expenses for 2010 (see note 27).
(16) Cash and Cash Equivalents
Details of this caption of the consolidated balance sheet at 31 December 2010 and 2009 are as follows:
Thousands of Euros
31/12/10 31/12/09
Current deposits
211,564 237,801
Cash at banks
28,085 11,571
Total cash and cash equivalents
239,649 249,372
Current deposits mainly include the surplus of funds from the issue of bonds in the USA during 2009 (see note 5 (a)).

66

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Details of cash and cash equivalents at 31 December 2010 and 2009 by currency are as follows:
Thousands of Euros
31/12/10 31/12/09
Currency
Euro
4,268 2,153
US Dollar
202,942 208,800
Other currency
32,439 38,419
239,649 249,372
(17) Equity
Details of consolidated equity and changes are shown in the consolidated statement of changes in equity, which forms an integral part of the consolidated financial statements.
(a) Share capital
At 31 December 2010 and 2009 the Company’s share capital is represented by 213,064,899 ordinary shares of Euros 0.50 par value each, which are subscribed and fully paid and have the same voting and profit-sharing rights.
These shares are freely transferable.
The Company only has information on the identity of its shareholders when this information is provided voluntarily or to comply with prevailing legislation. Based on the information available to the Company, its most significant shareholders at 31 December 2010 and 2009 are as follows:
Percentage ownership
31/12/10 31/12/09
Scranton Enterprises,B.V.
7.58 % 10.65 %
Capital Research and Management Company
10.02 % —
Other
82.40 % 89.35 %
100.00 % 100.00 %
(b) Share premium
There have been no movements in share premium during 2010 and 2009. In 2008 dividends were paid from share premium amounting to Euros 10,030 thousand.

67

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(c) Reserves
The availability of the reserves for distribution is subject to legislation applicable to each of the Group companies. At 31 December 2010, Euros 28,876 thousand equivalent to the carrying amount of development costs pending amortisation of certain Spanish companies (Euros 25,987 thousand at 31 December 2009) (see note 8) are, in accordance with applicable legislation, restricted reserves which cannot be distributed until these development costs have been amortised.
Companies in Spain are obliged to transfer 10% of each year’s profits to a legal reserve until this reserve reaches an amount equal to 20% of share capital. This reserve is not distributable to shareholders and may only be used to offset losses if no other reserves are available. Under certain conditions it may be used to increase share capital provided that the balance left on the reserve is at least equal to 10% of the nominal value of the total share capital after the increase.
At 31 December 2010 the legal reserve of the Parent has been fully appropriated and amounts to Euros 21,306 thousand (Euros 18,657 thousand at 31 December 2009).
Distribution of the legal reserves of Spanish companies is subject to the same restrictions as those of the Parent Company and at 31 December 2010 and 2009 the balance of the legal reserve of other Spanish companies amounts to Euros 2,106 thousand.
Other foreign Group companies have a legal reserve amounting to Euros 692 thousand (Euros 654 thousand at 31 December 2009).
(d) Own shares
During the year ended 31 December 2009 the Company has carried out the following operations with own shares:
Thousands of
No. of shares Euros
Balance at 1 January 2009
2,411,622 33,087
Acquisitions
2,176,929 25,186
Disposals
(4,535,225 ) (57,596 )
Balance at 31 December 2009
53,326 677

68

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
During the year ended 31 December 2010 the Company has carried out the following operations with own shares:
Thousands of
No. of shares Euros
Balance at 1 January 2010
53,326 677
Acquisitions
105,000 1,250
Balance at 31 December 2010
158,326 1,927
As a result, the Company holds own shares equivalent to 0.07% of its capital at 31 December 2010 (0.03% at 31 December 2009).
(e) Distribution of profits
The profits of Grifols, S.A. and subsidiaries will be distributed as agreed by respective shareholders of each company at their general meetings.
The Board of directors of Grifols, S.A. will propose to the shareholders at their annual general meeting that the profit of Grifols, S.A. for the year ended 31 December 2010, amounting to Euros 63,548 thousand, be transferred to reserves.
The distribution of the Company’s profit for the year ended 31 December 2009 is presented in the consolidated statement of changes in equity.
The dividend per share distributed at 30 June 2009 is as follows:
30/06/2009
% of par Euro per Amount
value share (Thousands of Euros)
Ordinary shares
46 0.23 48,691
Total dividends paid in June 2009
46 0.23 48,691
Dividends with a charge to profits
46 0.23 48,691
Total dividends paid in June 2009
46 0.23 48,691

69

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
The dividend per share (interim dividend) distributed in December 2009 is as follows:
31/12/2009
% of par Euro per Amount
value share (Thousands of Euros)
Ordinary shares
30 0.15 31,960
Total dividends paid in December 2009
30 0.15 31,960
Interim dividend
30 0.15 31,960
Total dividends paid in December 2009
30 0.15 31,960
The dividend per share distributed in July 2010 is as follows:
31/07/2010
% of par Euro per Amount
value share (Thousands of Euros)
Total dividends paid in July 2010 ( ordinary shares)
26 0.13 27,229
(f) Cash flow hedges
To cover the interest rate risk related to the planned issuance of corporate bonds by Grifols Inc. (see note 22) a swap was contracted in July 2009 to hedge the interest rate of 10-year US government bonds, with a nominal amount of US Dollars 200 million and maturity on 21 September 2009 (date of issuance of the bonds), swapping a variable interest rate for a fixed rate. The Group has recognised this derivative as hedging of cash flows from a highly probable transaction. At the date of redemption, the valuation resulted in a financial cost of Euros 3,275 thousand, which has been recognised in equity, net of the tax effect under “Cash flow hedges” and deferred over the term of the ten-year corporate bond (see notes 22 and 32).
(18) Earnings per Share
The calculation of basic earnings per share is based on the profit for the year attributable to the shareholders of the Company divided by the weighted average number of ordinary shares in circulation throughout the year, excluding own shares.

70

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Details of the calculation of basic earnings per share are as follows:
2010 2009 2008
Profit for the year attributable to equity holders of the Company (thousands of Euros)
115,513 147,972 121,728
Weighted average number of ordinary shares in circulation
212,909,162 209,451,806 210,707,597
Basic earnings per share (Euros per share)
0.54 0.71 0.58
The weighted average number of ordinary shares issued is determined as follows:
Number of shares
2010 2009 2008
Issued ordinary shares at 1 January
213,011,573 210,653,277 210,964,436
Effect of own shares
(102,411 ) (1,201,471 ) (256,839 )
212,909,162 209,451,806 210,707,597
Diluted earnings per share are calculated by dividing profit attributable to shareholders of the Company by the weighted average number of ordinary shares in circulation considering the diluting effects of potential ordinary shares. At 31 December 2010, 2009 and 2008 basic and diluted earnings per share are the same as no potential diluting effects exist.
(19) Non-controlling Interests
Details of non-controlling interests and movement during the year ended 31 December 2009 are as follows:
Thousands of Euros
Balances at Business Translation Balances at
31/12/08 Additions combinations Dividends differences 31/12/09
Grifols (Thailand) Pte Ltd
977 308 — (112 ) 30 1,203
Grifols Malaysia Sdn Bhd
273 35 — — (5 ) 303
Woolloomooloo Holdings Pty Ltd.
— (745 ) 9,876 (106 ) 1,626 10,651
1,250 (402 ) 9,876 (218 ) 1,651 12,157
(note 3(b))

71

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Details of non-controlling interests and movement during the year ended 31 December 2010 are as follows:
Thousands of Euros
Balances at Translation Balances at
31/12/09 Additions Dividends differences 31/12/10
Grifols (Thailand) Pte Ltd
1,203 367 (108 ) 255 1,717
Grifols Malaysia Sdn Bhd
303 302 — 76 681
Woolloomooloo Holdings Pty Ltd.
10,651 (915 ) (158 ) 2,374 11,952
12,157 (246 ) (266 ) 2,705 14,350
(20) Grants
Details are as follows:
Thousands of Euros
31/12/10 31/12/09
Capital grants
1,830 2,025
Interest-rate grants (preference loans)
258 286
Grants
2,088 2,311

72

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Details of capital grants are as follows:
Thousands of Euros
31/12/10 31/12/09
Total amount of capital grant:
Prior to 1995
330 330
1995
627 627
1996
54 54
1997
426 426
1998
65 65
1999
42 42
2000
181 181
2001
214 214
2002
626 626
2004
1,940 1,940
2005
35 35
2006
35 35
2007
33 33
2008
124 124
2009
742 742
Current period
323 —
5,797 5,474
Less, revenues recognised:
Prior years
(3,140 ) (2,444 )
Current year
(612 ) (696 )
(3,752 ) (3,140 )
Translation differences
(215 ) (309 )
Net value of capital grants
1,830 2,025
At 31 December 2010 interest-rate grants (preference loans) include Euros 258 thousand (Euros 286 thousand at 31 December 2009) of implicit interest on loans extended by the Spanish Ministry of Science and Technology as these are interest free.

73

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Movement during 2008 is as follows:
Balances at Transfers to Balances at
31/12/07 Additions profit or loss 31/12/08
Interest-rate grants (preference loans)
2,463 561 (2,686 ) 338
Movement during 2009 is as follows:
Balances at Transfers to Balances at
31/12/08 Additions profit or loss 31/12/09
Interest-rate grants (preference loans)
338 440 (492 ) 286
Movement during 2010 is as follows:
Balances at Transfers to Balances at
31/12/09 Additions profit or loss 31/12/10
Interest-rate grants (preference loans)
286 88 (116 ) 258
(21) Provisions
Details of provisions at 31 December 2010 and 2009 are as follows:
Thousands of Euros
Non-current provisions (a) 31/12/10 31/12/09
Provisions for pensions and similar obligations
787 595
Other provisions
591 637
Non-current provisions
1,378 1,232
Thousands of Euros
Current provisions (b) 31/12/10 31/12/09
Trade provisions
4,365 4,702
(a) Non-current provisions
At 31 December 2010 and 2009 provisions for pensions and similar obligations mainly comprise a provision made by certain foreign subsidiaries in respect of labour commitments with certain employees.

74

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Movement in non-current provisions during 2009 is as follows:
Thousands of Euros
Balances Balances
at Business Translation at
31/12/08 combination Reversal Cancellation differences 31/12/09
Non-current provisions
3,045 102 (1,411 ) (457 ) (47 ) 1,232
Movement in non-current provisions during 2010 is as follows:
Thousands of Euros
Balances at Translation Balances at
31/12/09 Charge Cancellation differences 31/12/10
Non-current provisions
1,232 140 (71 ) 77 1,378
(b) Current provisions
Movement in trade provisions during 2009 is as follows:
Thousands of Euros
Balances at Business Translation Balances at
31/12/08 combination Charge differences 31/12/09
Trade provisions
3,830 198 636 38 4,702
Movement in trade provisions during 2010 is as follows:
Thousands of Euros
Balances at Translation Balances at
31/12/09 Charge Cancellation differences 31/12/10
Trade provisions
4,702 41 (414 ) 36 4,365

75

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(22) Financial Liabilities
This note provides information on the contractual conditions of the loans obtained by the Group, which are measured at amortised cost, except for the financial derivative, which is measured at fair value. For further information on exposure to interest rate risk, currency risk and liquidity risk and the fair values of financial liabilities, please refer to note 32.
a) Non-current financial liabilities
Details at 31 December 2010 and 2009 are as follows:
Thousands of Euros
Non-current financial liabilities 31/12/10 31/12/09 31/12/08
Corporate bonds (a.1.1)
441,203 410,552 —
Bonds
441,203 410,552 —
Club Deal (a.1.2)
99,408 195,471 225,320
Other loans (a.1.2)
120,040 90,961 79,069
Finance lease liabilities (a.1.3)
4,734 6,202 7,124
Loans and borrowings
224,182 292,634 311,513
Loans and borrowings and bonds or other non-current marketable securities (a.1)
665,385 703,186 311,513
Preference loans extended by the Spanish Ministry of Science and Technology (a.2)
9,744 11,135 10,685
Debt on the acquisition of the plasma centre (a.2)
530 1,050 1,098
Other
200 367 759
Other non-current financial liabilities (a.2)
10,474 12,552 12,542
675,859 715,738 324,055

76

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Non-current loans and borrowing arrangements are shown net of the loan arrangement expenses which are pending amortisation:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Loan arrangement expenses
1,365 2,105 2,245
(a.1) Loans and borrowings and bonds or other non-current marketable securities
(a.1.1) Corporate Bonds
On 21 September 2009 the Group, through Grifols, Inc., concluded the first private placement of corporate bonds in the USA totalling US Dollars 600 million. The issue was subscribed by 22 qualified investors, 90% in US Dollars and the remaining 10% in Pounds Sterling and Euros. The issue was structured in three tranches: US Dollars 200 million at 12 years, US Dollars 300 million at 10 years and US Dollars 100 million at 7 years, with spreads over the yields of the 10 year US Treasury bond of 370 basis points for those issued at 12 years, 350 basis points for those issued at 10 years and 335 basis points for 7 year bonds.
A summary of corporate bonds at 31 December 2010 is as follows:
Amount Duration (years) Fixed interest rate
100,000
Thousands of USD
7 6.42 %
245,000
Thousands of USD
10 6.94 %
200,000
Thousands of USD
12 7.14 %
10,000
Thousands of EUR
10 6.94 %
25,000
Thousans of GBP
10 6.94 %
Funds raised have enabled the Group to extend the term of its financial borrowings from current to non-current, at the same time ensuring the availability of financial resources required to consolidate its plans for the future. Funds raised have therefore been used to settle current and non-current liabilities and the remaining amount has been used in current investments classified under “Cash and cash equivalents” for an equivalent amount of Euros 211,539 thousand at 31 December 2010 (Euros 237,777 thousand at 31 December 2009). This amount has been invested mainly in US Dollar deposits with financial institutions of recognised solvency.
With the issuance of the bonds, an interest rate hedge was contracted for the interest on the 10-year loan from the US government (see notes 17 (f) and 32).

77

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
This issue of corporate bonds is subject to compliance with certain financial ratio covenants. At 31 December 2010 and 2009 the Group complies with these financial ratio covenants.
Details of and movements related to the issue of corporate bonds are as follows:
Thousands of Euros
31/12/10 31/12/09
Opening balance
Issuance of corporate bonds in the USA
416,465 409,411
Transaction costs
(5,913 ) (5,967 )
410,552 403,444
Movements
Transferred to profit and loss
660 150
Corporate bonds issued in the USA, exchange differences
(1,772 ) 338
Translation differences
31,763 6,620
Closing balance
Corporate bonds issued in the USA
446,918 416,465
Transaction costs
(5,715 ) (5,913 )
441,203 410,552
(a.1.2) Other non-current loans and borrowings
Details of the terms and conditions of non-current loans and borrowings at 31 December 2010 and 2009 are included in Appendix IV, which forms an integral part of these notes to the consolidated financial statements.
At 26 May 2008 a Club Deal refinancing agreement was signed with 24 financial entities for Euros 350 million (including the option to draw down a tranche of the loan in US Dollars), in order to refinance the non-current syndicated loan then existing. This loan provided the Group with a significant margin for leverage to carry out planned investment programmes.
This syndicated loan, which matures on 26 May 2013, is subject to compliance with certain financial ratio covenants. In accordance with the agreed-upon conditions, the level of compliance with financial ratios and levels is determined at year end. The Company is required to provide financial information to the lending banks within the six-month period subsequent to 31 December of each year for the duration of the contract.

78

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
In 2009 the 24 financial entities and the Company unanimously agreed to a novation of the syndicated loan. The net financial debt/equity ratio was replaced by the minimum equity ratio. This replacement unifies all syndicated loan ratios with the bond issuance carried out by the Group in the USA.
At 31 December 2010 and 2009 the Group fulfilled the financial covenants established in the syndicated loan contract.
(a.1.3) Finance lease liabilities
Details of minimum payments and the current finance lease liabilities, by maturity date, are as follows:
Thousands of Euros
31/12/10 31/12/09
Current Non-current Current Non-current
Minimum payments
3,552 5,089 5,088 6,675
Interest
(272 ) (355 ) (354 ) (473 )
Present value
3,280 4,734 4,734 6,202
Thousands of Euros
31/12/10 31/12/09
Minimum Minimum Present
payments Interest Present value payments Interest value
Maturity at:
Less than one year
3,552 272 3,280 5,088 354 4,734
Two years
2,411 161 2,250 3,364 200 3,164
Three years
1,271 96 1,175 1,382 114 1,268
Four years
763 50 713 831 72 759
Five years
314 23 291 577 41 536
More than five years
330 25 305 521 46 475
Total
8,641 627 8,014 11,763 827 10,936

79

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(a.1.4) Maturity of non-current loans and borrowings and bonds
Details of maturity of non-current loans and borrowings and bonds at 31 December 2010 and 2009 are as follows:
Thousands of Euros
31/12/10 31/12/09
Maturity at:
Two years
85,171 81,388
Three years
51,582 79,696
Four years
17,936 75,905
Five years
17,548 12,506
More than five years
493,148 453,691
665,385 703,186
(a.2) Other non-current financial liabilities
Details of the interest-free preference loans extended by the Spanish Ministry of Science and Technology to various group companies are as follows:
Thousands of Euros
31/12/10 31/12/09
Date Amount Non- Non-
Company awarded awarded current Current current Current
Instituto Grifols S.A
31/01/2001 637 — — — 86
Instituto Grifols S.A
13/02/2002 691 — 94 89 94
Instituto Grifols S.A
17/01/2003 1,200 157 165 307 165
Instituto Grifols S.A
13/11/2003 2,000 520 279 762 279
Instituto Grifols S.A
17/01/2005 2,680 1,031 375 1,345 375
Instituto Grifols S.A
29/12/2005 2,100 1,025 288 1,253 288
Instituto Grifols S.A
29/12/2006 1,700 1,015 234 1,190 234
Instituto Grifols S.A
27/12/2007 1,700 1,164 232 1,324 —
Instituto Grifols S.A
31/12/2008 1,419 1,175 — 1,131 —
Instituto Grifols S.A
16/01/2009 1,540 1,294 — 1,249 —
Laboratorios Grifols, S.A
20/03/2001 219 — — — 30
Laboratorios Grifols, S.A
29/01/2002 210 — 29 27 29
Laboratorios Grifols, S.A
15/01/2003 220 29 30 56 30
Laboratorios Grifols, S.A
26/09/2003 300 76 41 111 41
Laboratorios Grifols, S.A
22/10/2004 200 77 28 100 28
Laboratorios Grifols, S.A
20/12/2005 180 88 25 107 25
Laboratorios Grifols, S.A
29/12/2006 400 233 54 273 54
Laboratorios Grifols, S.A
27/12/2007 360 212 42 242 —
Laboratorios Grifols, S.A
31/12/2008 600 497 — 478 —
Diagnostic Grifols, S.A
27/11/2008 857 358 129 468 129
Diagnostic Grifols, S.A
25/05/2010 203 116 31 — —
Grifols Engineering, S.A.
21/04/2009 524 427 34 447 —
Grifols Engineering, S.A.
21/04/2009 203 165 13 176 —
Grifols Engineering, S.A.
28/01/2010 100 85 — — —
20,243 9,744 2,123 11,135 1,887

80

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
During 2010 the implicit borrowing costs taken to profit and loss amount to Euros 567 thousand (Euros 616 thousand in 2009 and Euros 516 thousand in 2008) (see note 28).
At 31 December 2010, this caption also includes Euros 555 thousand (Euros 1,133 thousand at 31 December 2009) comprising the Euros equivalent of the debt in US Dollars payable in the long term to Amerihealth Plasma, LLC for the plasma centre acquired in the USA. Deferred finance expenses resulting from this transaction amount to Euros 25 thousand (Euros 83 thousand at 31 December 2009) and are deducted from the aforementioned amount. Other current financial liabilities include the current portion of this debt which amounts to Euros 637 thousand (Euros 442 thousand at 31 December 2009).
Details of the maturity of other non-current financial liabilities are as follows:
Thousands of Euros
31/12/10 31/12/09
Maturity at:
Two years
2,964 2,632
Three years
2,159 2,883
Four years
1,989 2,026
Five years
1,266 1,867
More than five years
2,096 3,144
10,474 12,552

81

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
b) Current financial liabilities
Details at 31 December 2010 and 2009 are as follows:
Thousands of Euros
Current financial liabilities 31/12/10 31/12/09
Bonds (b.1.1)
8,235 6,407
Interest of issue corporate bonds in the USA (b.1.1)
7,207 6,716
Bonds
15,442 13,123
Club Deal (b.1.2)
66,250 33,014
Other loans (b.1.2)
106,663 63,120
Finance lease liabilities (a.1.3)
3,280 4,734
Loans and borrowings
176,193 100,868
Loans and borrowings and bonds and other marketable securities (b.1)
191,635 113,991
Financial derivatives (note 32)
8,560 3,333
Preference loans extended by the Spanish Ministry of Science and Technology (a.2)
2,123 1,887
Receivables from social security affiliated entities transferred to a financial institution (b.2)
6,503 5,459
Debt on the acquisition of the plasma centre (a.2)
637 442
Debt with Novartis (b.2)
— 779
Guarantee deposits received
149 59
Other current financial liabilities
264 271
Other current financial liabilities (b.2)
18,236 12,230
209,871 126,221
Current loans and borrowing arrangements are shown net of the loan arrangement expenses which are pending amortization:
Thousands of Euros
31/12/10 31/12/09
Loan arrangement expenses
707 825
Current loans and borrowing arrangements are shown include accrued interest amounting to Euros 483 thousand (Euros 538 thousand at 31 December 2009).

82

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(b.1) Loans and borrowings and bonds or other current marketable securities
(b.1.1) Bonds
Details at 31 December 2010 and 2009 are as follows:
Thousands of Euros
31/12/10 31/12/09
Promissory notes issued to bearer
8,373 6,510
Interest pending accrual on promissory notes issued to bearer
(138 ) (103 )
Interest accrued on corporate bonds
7,207 6,716
15,442 13,123
During 2010 and 2009 a Group company has issued bearer promissory notes at one year of Euros 3,000 nominal amount each and an interest rate of 5.00% and 4.75%, respectively, which were earmarked for Group employees.
Details of the issue of bearer promissory notes to group employees are as follows:
31/12/09
Promissory
Nominal notes Interest pending
amount subscribed accrual
Maturity (Thousands Interest (Thousands (Thousands of
Issue date date of Euros) rate of Euros) Euros)
Issue of bearer promissory notes
05/05/09 05/05/10 3.000 4.75 % 6,510 (103 )
31/12/10
Promissory
Nominal notes Interest pending
amount subscribed accrual
Maturity (Thousands Interest (Thousands (Thousands of
Issue date date of Euros) rate of Euros) Euros)
Issue of bearer promissory notes
05/05/10 05/05/11 3.000 5.00 % 8,373 (138 )

83

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(b.1.2) Other current loans and borrowings
Details of current loans and borrowings are as follows:
Interest Thousands of Euros
rate (*) Drawn down
Min - max 31/12/10 31/12/09
Loans in:
US Dollars
5.00 % 1,384 3,010
Euros
1.17% - 6 % 143,990 73,664
Other currencies
TIIE+2% -15% 26,368 18,449
171,742 95,123
Discounted trade notes (note 13)
1.4-4.69 % 1,396 1,298
Current interest on loans and borrowings
483 538
Finance lease payables
3,552 5,088
177,173 102,047
Less, current portion of deferred finance expenses for leasing (272 ) (354 )
Less, current portion of loan arrangement expenses (708 ) (825 )
176,193 100,868
(*) Loans accrue variable interest rates.
At 31 December 2010 the Group has a drawable borrowing limit of Euros 704,315 thousand (Euros 703,231 thousand at 31 December 2009).
(b.2) Other current financial liabilities
At 31 December 2010 and 2009 other current financial liabilities also include approximately Euros 6,503 thousand and Euros 5,459 thousand, respectively, which were paid directly by social security affiliated entities and are transferable to Deutsche Bank, S.A.E. under contracts (see note 13).
At 31 December 2009 this caption included an outstanding receivable of Euros 779 thousand from Novartis Vaccines and Diagnostics, Inc. for the licence contract signed by a Group company during 2006. At 31 December 2010 this debt has been fully repaid.

84

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(23) Trade and Other Payables
Details are as follows:
Thousands of Euros
31/12/10 31/12/09
Suppliers and trade payables
160,678 120,887
Other
— 22
Suppliers
160,678 120,909
Public entities, other payables
11,928 17,832
Other trade payables
11,928 17,832
Current income tax liabilities
4,172 3,258
176,778 141,999
Suppliers
Details of related parties are shown in note 33.
Balances with suppliers include the following payables in foreign currencies:
Thousands of Euros
31/12/10 31/12/09
Currency
US Dollar
58,932 31,377
Chilean Peso
1,490 894
Swiss Franc
897 686
Czech Crown
568 380
Brazilian Real
428 621
Pound Sterling
405 266
Other currencies
665 1,419
The Group’s exposure to currency risk and liquidity risk associated with trade and other payables is described in note 32.

85

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Public entities, other payables
Details are as follows:
Thousands of Euros
31/12/10 31/12/09
Taxation authorities, VAT/Canary Islands Tax
3,472 3,292
Taxation authorities, withholdings
3,119 8,184
Social Security
3,246 3,027
Other public entities
2,091 3,329
Public entities, other payables
11,928 17,832
At 31 December 2010, Other public entities include a Euros 1,860 thousand provision (Euros 2,781 thousand at 31 December 2009) recognised as a result of a different interpretation of a specific tax situation which could be made by the current tax inspection (see note 29 (c)).
Current tax liabilities
Details are as follows:
Thousands of Euros
31/12/10 31/12/09
Taxation authorities, income tax:
Current year
4,161 3,185
Prior years
11 73
Current tax liabilities
4,172 3,258
(24) Other Current Liabilities
Details at 31 December are as follows:
Thousands of Euros
31/12/10 31/12/09
Salaries payable
28,321 24,367
Other payables
2,629 1,754
Other current liabilities
30,950 26,121

86

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(25) Revenues
Revenues are mainly generated by the sale of goods.
The distribution of net consolidated revenues for 2010, 2009 and 2008, by segment, was as follows:
%
31/12/10 31/12/09 31/12/08
Bioscience
78 % 76 % 76 %
Diagnostics
11 % 10 % 10 %
Hospital
9 % 10 % 10 %
Raw materials
1 % 3 % 3 %
Others
1 % 1 % 1 %
100 % 100 % 100 %
The geographical distribution of net consolidated revenues is as follows:
%
31/12/10 31/12/09 31/12/08
Spain
23 % 25 % 24 %
European Union
21 % 22 % 26 %
United States
34 % 32 % 36 %
Rest of the world
22 % 21 % 14 %
100 % 100 % 100 %
Net consolidated revenues include net sales made in the following foreign currencies:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Currency
US Dollar
405,439 349,064 304,445
Pound Sterling
36,199 33,668 36,668
Chilean Peso
28,760 21,083 16,047
Mexican Peso
25,652 36,472 29,182
Brazilian Real
21,949 21,262 15,916
Australian Dollar
13,950 6,387 —
Czech Crown
13,698 12,863 12,568
Argentinean Peso
13,122 11,323 9,145
Polish Zloty
11,668 13,525 —
Other currency
18,989 18,013 13,062

87

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(26) Personnel Expenses
Details are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Wages and salaries
232,174 219,803 191,644
Contributions to pension plans (note 31)
1,615 1,571 1,365
Other social charges
8,615 8,072 6,310
Social Security
46,604 43,722 38,840
289,008 273,168 238,159
(27) Other Operating Income and Expenses
Other operating expenses
Details are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Changes in trade provisions (notes 21 (b) and 32)
398 1,348 561
Professional services (note 15)
40,530 25,266 22,874
Commissions
8,038 7,711 7,075
Supplies and other materials
30,544 28,859 26,874
Operating leases (note 30 (a))
19,272 17,364 16,583
Freight
20,956 20,518 19,485
Repairs and maintenance costs
22,480 21,365 17,642
Advertising
14,708 15,580 16,872
Insurance
10,807 10,803 10,367
Royalties and service charges
884 4,954 8,760
Travel expenses
12,742 11,935 14,210
External services
24,603 25,024 21,891
Others
14,256 12,654 9,094
Other operating expenses
220,218 203,381 192,288
Research and development expenses incurred by the Group (including personnel expenses and amortization of intangible assets and property, plant and equipment) amount to Euros 36.6 million in 2010 (Euros 35.2 million in 2009 and Euros 25.6 million in 2008).

88

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Other operating income
Details are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Income from insurance claims
771 807 584
Grants
307 378 497
Other income
118 258 208
Other operating income
1,196 1,443 1,289
(28) Finance Income and Expense
Details are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Interest from Social Security
2,876 6,510 2,212
Other finance income
1,650 557 470
Finance income
4,526 7,067 2,682
Syndicated loan (other finance expenses)
(1,172 ) (747 ) (1,849 )
Syndicated loan (interest)
(3,303 ) (6,289 ) (12,152
Finance expenses from sale of receivables (note 13)
(5,378 ) (2,531 ) (2,128 )
Interests costs of Corporate bonds issued in the USA (note 22)
(31,923 ) (6,766 ) —
Implicit interest on preference loans (note 22 (a2))
(567 ) (616 ) (516 )
Capitalised interest
2,399 1,278 —
Other finance expenses
(9,716 ) (11,416 ) (12,660 )
Finance expenses
(49,660 ) (27,087 ) (29,305 )
Change in fair value of financial derivatives (note 32)
(7,593 ) (587 ) (1,268 )
Impairment and profit / (losses) on disposal of financial instruments
91 (245 ) —
Exchange differences
1,616 (1,733 ) (2,825 )
Net finance income and expense
(51,020 ) (22,585 ) (30,716 )

89

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
During 2010 the Group has capitalised interest at a rate of between 2.6% and 7.1% based on the financing received (between 3% and 4% during 2009) (see note 4 (f)).
(29) Taxation
Companies present annual income tax returns. The standard rate of tax is 30% for Spanish companies, which may be reduced by certain credits.
Grifols, S.A. is authorised to present a consolidated tax return with Diagnostic Grifols, S.A., Movaco, S.A., Laboratorios Grifols, S.A., Instituto Grifols, S.A., Logister, S.A., Biomat, S.A., Grifols Viajes, S.A., Grifols International, S.A., Grifols Engineering, S.A., Arrahona Optimus, S.L. and Gri-Cel, S.A. (since 2009). Grifols, S.A., in its capacity as parent, is responsible for the presentation and payment of the consolidated tax return.
The North-American company Grifols, Inc. is also authorised to present consolidated tax returns in the USA with Grifols Biologicals, Inc., Grifols USA, LLC, Biomat USA, Inc. and Plasmacare, Inc.
a) Reconciliation of accounting and taxable income
Details of the income tax expense are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Profit for the year before income tax
157,784 203,994 172,269
Tax at 30%
47,335 61,198 51,680
Permanent differences
2,300 1,935 2,678
Effect of different tax rates
3,346 5,159 4,366
Tax credits for research and development
(7,281 ) (8,106 ) (5,403 )
Other tax credits (deductions)
(3,516 ) (4,548 ) (4,199 )
Other income tax expenses
333 786 1,031
Total income tax expense
42,517 56,424 50,153
Deferred tax expenses
15,547 8,832 6,987
Current income tax
26,970 47,592 43,166
Total
42,517 56,424 50,153

90

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Deferred tax assets and liabilities
Details of deferred tax assets and liabilities are as follows:
Tax Effect
31/12/10 31/12/09 31/12/08
Thousands of Euros
Assets
Tax credits (deductions)
4,830 5,992 13,215
Tax loss carryforwards
1,233 88 163
Fixed assets, amortisation and depreciation
998 728 299
Unrealised margins on inventories
19,256 19,814 17,222
Provision for bad debts
395 444 281
Inventories
235 225 1,004
Cash flow hedges
1,120 1,247 —
Other provisions
4,297 2,439 825
Others
2,525 2,418 1,187
34,889 33,395 34,297
Liabilities
Goodwill
17,948 15,186 12,423
Revaluations of assets
15,210 15,011 15,345
Fixed assets, amortisation and depreciation
40,520 23,873 14,028
Finance leases
3,396 3,634 3,647
Inventories
— — 2,041
Provision for investments
696 873 2,322
Others
1,371 1,748 2,163
79,141 60,325 51,969

91

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Movement in deferred tax assets and liabilities is as follows:
Thousands of Euros
Deferred tax assets 2010 2009 2008
Balance at 1 January
33,395 34,297 34,110
Movements during the year
865 (1,478 ) 687
Business combinations (note 3)
— 500 —
Adjustments for changes in tax rate through profit and loss
— 69 (514 )
Translation differences
629 7 14
Balance at 31 December
34,889 33,395 34,297
Thousands of Euros
Deferred tax liabilities 2010 2009 2008
Balance at 1 January
60,325 51,969 43,794
Movements during the year
16,537 7,423 6,721
Business combinations (note 3)
— 1,761 —
Adjustments for changes in tax rate through profit and loss
— — 439
Translation differences
2,279 (828 ) 1,015
Balance at 31 December
79,141 60,325 51,969
As permitted by Royal Decree — Law 3/1993 governing urgent tax and financial measures and Royal Decrees — Law 7/1994 and Law 2/1995 governing accelerated depreciation of property, plant and equipment for investments which generate employment, the Spanish companies have opted to apply accelerated depreciation to certain additions to property, plant and equipment, which has resulted in the corresponding deferred tax liability.

92

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Details of deferred tax assets and liabilities on items directly debited and credited to equity during the year are as follows:
Thousands of Euros
Tax effect
31/12/10 31/12/09 31/12/08
Available-for-sale financial assets
— (69 ) 3
Cash flow hedges (note 17 (g))
127 1,247 —
127 1,178 3
The remaining assets and liabilities recognised in 2010, 2009 and 2008 were recognised on the income statement.
The Spanish consolidated companies have deductions pending application at 31 December 2010 and 2009 mainly in respect of research and development, which are detailed below:
Year of origin 2010 2009 Applicable through
2008
101 417 2023
2009
500 5,575 2024
2010
4,229 — 2025
4,830 5,992
At 31 December 2010 the Group recognised a tax credit of Euros 4,830 thousand (Euros 5,992 thousand at 31 December 2009) from the deductions pending application, as its future recovery was reasonably assured.
At 31 December 2010 the Group has future tax deductions of Euros 23,685 thousand (Euros 25,806 thousand at 31 December 2009) pending application as a result of goodwill generated on the acquisition of Biomat USA, Inc. This amount will be deducted annually from the taxable profits until 2022, without being limited by the amount of tax payable in any one year. The amount that will be deducted in 2010 at the rate of 30% will be Euros 2,121 thousand. The Group has recognised a deferred tax liability of Euros 14,848 thousand in respect of this item at 31 December 2010 (Euros 12,727 thousand at 31 December 2009).

93

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
At 31 December 2010 the Group also has future tax deductions of Euros 9,727 thousand (Euros 10,368 thousand at 31 December 2009) pending application as a result of goodwill generated on the acquisition of Plasmacare, Inc. This amount will be deducted annually from the taxable profits until 2026, without being limited by the amount of tax payable in any one year. The amount deducted in 2010 at the rate of 30% has been Euros 641 thousand. The Group has recognised a deferred tax liability of Euros 3,100 thousand in respect of this item at 31 December 2010 (Euros 2,459 thousand at 31 December 2009).
At 31 December 2010 the Group has recognised loss carryforwards of Euros 1,233 thousand (Euros 88 thousand at 31 December 2009 and Euros 163 at 31 December 2008), of which, Euros 1,187 thousand correspond to the Australian company Woolloomooloo Holdings Pty. Ltd., whilst Euros 46 thousand relate to the US company Grifols USA, LLC.
The Group has not recognised the tax effect of loss carryforwards of Euros 1,231 thousand (Euros 1,117 thousand at 31 December 2009 and Euros 635 thousand at 31 December 2008) from Grifols Portugal as deferred tax assets. The remaining companies do not have significant loss carryforwards which have not been recognised.
c) Years open to inspection
In accordance with current legislation, taxes cannot be considered definitive until they have been inspected and agreed by the taxation authorities or before the prescribed inspection period has elapsed.
During 2010 the following events arose in relation to the tax inspections performed in Group companies:
• On 30 June 2010, in relation to the inspection underway on Grifols, S.A., Instituto Grifols, S.A., Laboratorios Grifols, S.A. and Movaco, S.A., the Group has received assessments for income tax, value added tax (VAT), personal income tax and withholding tax on investment income. The total amount settled was Euros 586 thousand and the income tax expense amounts to Euros 1,257 thousand.
• During 2010 the tax inspection on the income tax, VAT and withholdings for 2006 of Grifols Italia, S.p.A. was concluded, implying no significant payment for the Group.
• Logística Grifols, S.A. de CV: Tax ruling on the financial statements for 2005 and 2006. Group management does not expect any significant liabilities to arise as a result of this inspection.

94

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
• At 30 June 2010 Grifols, Inc. and subsidiaries received notification of income tax inspection for the years closed 31 December 2006, 2007 and 2008. Due to, among other reasons, differences in the interpretation of prevailing tax legislation, the Group’s directors have set up a provision of Euros 1,860 thousand, which is recognised under “income tax” in the income statement and under “public entities, other “ in the balance sheet (see note 23).
• Grifols Brasil, Lda.: Tax on circulation of goods and services (ICMS) for 2006 to 2010. Group management does not expect that any significant liability will arise from this inspection.
During 2009 the following events arose in relation to the tax inspections:
• Notification of the completion of the inspection of Biomat USA, Inc., resulting in a favourable conclusion.
During 2008 the following events had arisen in relation to the tax inspections performed in Group companies:
• Notification of the favourable completion of the inspection of Grifols Deutschland, except for Euros 150 thousand which was taken to profit and loss in 2008.
• Notification of the favourable completion of the inspection of Grifols, Inc., Grifols Biologicals, Inc., Grifols USA, Inc. and Plasmacare, Inc.
(30) Operating Leases
(a) Operating leases (as lessee)
At 31 December 2010 and 2009 the Group leased buildings from third parties under operating leases.
The Group has warehouses and buildings contracted under operating lease. The duration of these lease contracts ranges from between 1 to 30 years. Contracts may be renewed on termination. Lease instalments are adjusted periodically in accordance with the price index established in each contract. One Group company has entered into lease contracts which include contingent rents. These contingent rents have been based on production capacity, surface area used and the real estate market and are expensed on a straight line basis.

95

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Operating lease instalments of Euros 19,272 thousand have been recognised as an expense for the year at 31 December 2010 (Euros 17,364 thousand at 31 December 2009 and 16,583 thousand at 31 December 2008) (see note 27).
Future minimum payments on non-cancellable operating leases at 31 December are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Maturity:
Up to 1 year
13,769 10,098 9,575
Between 1 and 5 years
31,003 25,943 24,919
More than 5 years
7,856 8,084 7,192
Total future minimum payments
52,628 44,125 41,686
(b) Operating leases (as lessor)
The Group has a building leased to third parties under an operating lease at 31 December 2010, 2009 and 2008. Future minimum payments receivable under non-cancellable operating leases are as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Maturity:
Up to 1 year
64 91 69
Between 1 and 5 years
21 56 50
More than 5 years
— 10 —
Total future minimum payments
85 157 119
This contract does not include contingent rents or purchase options. Income of Euros 96 thousand has been recognised in 2010 (Euros 85 thousand in 2009 and Euros 70 thousand in 2008).
(31) Other Commitments with Third Parties and Other Contingent Liabilities
(a) Guarantees
The Group has not extended any security or bank guarantees to third parties.

96

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(b) Obligations with personnel
As described in note 4 (q) section (i), Spanish companies of the Group are obliged to contribute to a defined contribution pension plan. Contributions made by the Group amounted to Euros 460 thousand in 2010 (Euros 416 thousand at 31 December 2009).
In successive years this contribution will be defined through labour negotiations.
Some foreign subsidiaries of the Group have made contributions of Euros 1,155 thousand to complementary pension schemes (Euros 1,155 thousand at 31 December 2009).
(c) Judicial procedures and arbitration
Details of legal proceedings in which the Company or Group companies are involved are as follows:
Instituto Grifols, S.A.
• Litigation was initiated in February 2000. Proceedings have been brought jointly against the Company and another plasma fractioning company.
The claimant (an individual) claimed Euros 542 thousand in damages due to the alleged contraction of HIV and Hepatitis C.
The first instance court in Cadiz fully rejected the claim against Instituto Grifols, S.A. on 25 November 2005.
An appeal was filed, which was rejected by the Cádiz Provincial Court in April 2007, thereby confirming the company’s line of defense. Notification was published on 3 February 2011 that on 19 January 2011 the Spanish High Court had fully rejected the appeal against the Cádiz Provincial Court’s decision to reject the claim against Instituto Grifols, S.A.
• A claim brought against the Health Board of Castilla y León in February 2005.
The defendant (an individual) claimed Euros 180 thousand in damages due to the alleged contraction of Hepatitis C. The health authorities requested that this claim be extended to include the Company.

97

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Notification was published on 2 February 2011 that this appeal has been rejected on 30 December 2010. This ruling is pending confirmation, unless it is appealed in the Spanish High Court.
• The Company was notified in 2007 of a claim for maximum damages of Euros 12,960 thousand filed by a group of 100 Catalan haemophiliacs against all plasma fractionation companies. During 2008 this claim was rejected by the Courts, and the ruling appealed by the group of haemophiliacs. Notification was published on 21 January 2011 that on 18 January 2011 the Barcelona Provincial Court had rejected the haemophiliacs’ claim. This ruling is pending confirmation, unless it is appealed in the Spanish High Court.
Grifols Biologicals, Inc.
• Legal proceedings (consent decree) which were brought against the plasma fractioning centre in Los Angeles.
The blood plasma fractioning centre in Los Angeles is managed through consent decree which was applied for in January 1998 to the Courts by the FDA and US Department of Justice as a result of an infringement of FDA regulations committed by the former owner of the centre (Alpha Therapeutic Corporation, hereinafter ATC). As a result of this consent decree, the Los Angeles centre is subject to strict FDA audits and may only sell products manufactured in the centre subsequent to prior authorisation.
The Company cannot guarantee if or when the consent decree will be lifted.
In March 2004 as a result of improvements to the centre made by the Group, the FDA awarded several free sales certificates for the former ATC products manufactured in this centre.
Based on the current level of compliance, there are no commercial activities that are prohibited or limited by the consent decree.
No provision has been made for these legal issues as the Group considers that these will not have a probable adverse impact.

98

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
(d) Long-term materials supply contract
The long-term supply contract for plasma signed by the Group in 2008 was terminated by the Group in 2009 on the grounds of failure by the supplier to meet certain contractual terms. The supplier has not accepted the arguments of the Group and both are presently holding negotiations to settle the dispute in arbitration proceedings, the Directors of the Group being of the opinion that the eventual settlement will not involve any significant additional costs.
(e) Agreement for the acquisition of Talecris Biotherapeutics Holdings Corp (Talecris)
On 6 June 2010 the Company entered into an agreement to acquire the American company Talecris Biotherapeutics, which also specialises in the production of plasma-derived biological medication, for a total of US Dollars 3,400 million.
This agreement will become effective subject to approval by the Defence of Competition authorities. In the event that this approval is not obtained, the Company will be required to pay US Dollars 375 million as indemnity for the damages caused.
The operation will be performed through a combined offer of cash and Grifols shares which would not carry the right to vote on new share issues.
The offer is made in relation to all Talecris shares and the price offered per share amounts to US Dollars 19 in cash and 0.641 shares in Grifols without the right to vote on new share issues. As a result of the ruling on the claim filed by certain shareholders of Talecris in the State of Delaware against Talecris, Cerburus, Grifols and the Agreement and Plan of Merger , appraisal rights have been granted to those Talecris shareholders who have requested them and Grifols has undertaken to issue 500,000 shares without additional voting rights which will be distributed amongst all of the shareholders of Talecris, except for Talecris Holdings LLC and the directors of Talecris. As a result of this additional share issue, the share exchange equation stands at (a) 0.641 shares without voting rights of Grifols for each Talecris share issued, at the closing date of the transaction, held by Talecris LLC and the directors of Talecris and (b) 0.6485 shares without voting rights of Grifols for each Talecris share issued, at the transaction closing date, held by the remaining shareholders.
On 6 June 2010 and in relation to this potential acquisition, the Company obtained financing commitments from six financial institutions for a total of US Dollars 4,500 million. This financing would be used to cover the cash payment of the acquisition and to refinance the existing debt.

99

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
On 23 November 2010 the Company signed loan agreements amounting to US Dollars 3,400 million for the purchase of Talecris. This amount forms part of the US Dollars 4,500 million collateralised on 6 June 2010. Details of this collateralised senior debt are as follows:
• Non-current syndicated financing with financial institutions: Loan repayable in 5 years totalling US Dollars 1,500 million. Margin of 375 basis points (bp) linked to US Libor and 400 bp linked to Euribor. BB and Ba3 rating.
• Non-current syndicated financing with institutional investors: 6 year bullet loan (payment of whole principal upon maturity) amounting to US Dollars 1,600 million. Margin of 425 bp linked to US Libor and 450 bp linked to Euribor. BB and Ba3 rating.
• Senior revolving credit facility amounting to US Dollars 300 million. BB and Ba3 rating.
This debt will be effective once the Talecris purchase transaction has been completed.
(32) Financial Instruments
Classification
Disclosure of financial instruments by nature and category is as follows:
Thousands of Euros
31/12/09
Financial
Available-for- assets /
sale financial Loans and (liabilities)held Debts and
assets receivables for trading payables
Non-current financial assets
501 3,230 — —
Other current financial assets
— 6,547 — —
Interest-rate swap
— — (3,333 ) —
Unquoted futures
— — 1,670 —
Trade and other receivables
239,204 — —
Bank loans
— — — (382,566 )
Other financial liabilities
— — — (21,449 )
Bonds and other securities
— — — (423,675 )
Finance lease liabilities
— — — (10,936 )
Trade and other payables
— — — (120,909 )
Other current liabilities
— — — (1,754 )
501 248,981 (1,663 ) (961,289 )

100

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Thousands of Euros
31/12/10
Financial
Available-for- assets /
sale financial Loans and (liabilities)held Debts and
assets receivables for trading payables
Non-current financial assets
535 7,000 — —
Other current financial assets
— 12,946 — —
Interest-rate swap
— — (1,809 ) —
Unquoted futures
— — (6,751 ) —
Trade and other receivables
— 259,497 — —
Bank loans
— — — (392,361 )
Other financial liabilities
— — — (20,150 )
Bonds and other securities
— — — (456,645 )
Finance lease liabilities
— — — (8,014 )
Trade and other payables
— — — (160,678 )
Payables for Group companies
— — — (1,162 )
Other current liabilities
— — — (2,629 )
535 279,443 (8,560 ) (1,041,639 )
Net losses and gains by financial instrument category
Details are as follows:
Financial assets
Thousands of Euros
31/12/09
Available-
Assets at fair for-sale
value through Loans and financial
profit or loss receivables assets Total
Finance income at amortised cost
— 7,067 — 7,067
Change in fair value
2,015 — — 2,015
Reclassification of equity to profit or loss
— — (172 ) (172 )
Net gains/(losses) in profit and loss
2,015 7,067 (172 ) 8,910
Change in fair value
— — 14 14
Net gains in equity
— — 14 14
Total
2,015 7,067 (158 ) 8,924

101

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Thousands of Euros
31/12/10
Available-
Assets at fair for-sale
value through Loans and financial
profit or loss receivables assets Total
Finance income at amortised cost
— 4,526 — 4,526
Change in fair value
1,601 — — 1,601
Net gains in profit and loss
1,601 4,526 — 6,127
Total
1,601 4,526 — 6,127
Financial liabilities
Thousands of Euros
31/12/09
Liabilities at
fair value
through profit Debts and Hedging
or loss payables derivatives Total
Finance expenses at amortised cost
— (27,087 ) — (27,087 )
Change in fair value
(2,602 ) — — (2,602 )
Reclassification of equity to profit or loss
— — (50 ) (50 )
Net losses in profit and loss
(2,602 ) (27,087 ) (50 ) (29,739 )
Change in fair value
— — 1,998 1,998
Net gains in equity
— — 1,998 1,998
Total
(2,602 ) (27,087 ) 1,948 (27,741 )

102

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Thousands of Euros
31/12/10
Liabilities at
fair value
through profit Debts and Hedging
or loss payables derivatives Total
Finance expenses at amortised cost
— (49,660 ) — (49,660 )
Change in fair value
(9,194 ) — — (9,194 )
Reclassification of equity to profit or loss
— — (197 ) (197 )
Net losses in profit and loss
(9,194 ) (49,660 ) (197 ) (59,051 )
Total
(9,194 ) (49,660 ) (197 ) (59,051 )
Fair value
The fair value of corporate bonds amounts to Euros 496 million at 31 December 2010. The valuation has been made based on observable market data. The interest rate swap, unquoted futures contract and hedging derivative are also measured at fair value using observable market data. These fair values are level 2 in fair value hierarchy, using other than quoted prices (level 1) that are observable for the assets/liabilities, either directly or indirectly.
The fair value of financial assets and the remaining financial liabilities does not differ significantly from their carrying amount.
Financial derivatives
a) Derivative financial instruments at fair value through profit or loss
Derivative financial instruments that do not meet the hedge accounting requirements are classified and measured as financial assets or financial liabilities at fair value through profit and loss.

103

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
The Group recognized the following swaps at 31 December 2009:
Thousands of Euros
Value at
Derivatives Par 31/12/09 Maturity
Interest rate swap
50,000 (3,333 ) 26/07/2013
(note 22)
Unquoted future
23,221 1,189 30/12/2010
Unquoted future
26,370 481 30/12/2010
49,591 1,670
(note 14)
The Group has recognized the following derivatives at 31 December 2010:
Thousands of Euros
Value at
Derivatives Par 31/12/10 Maturity
Interest rate swap
50,000 (1,809 ) 26/07/2013
Unquoted future
23,221 (2,821 ) 31/03/2011
Unquoted future
26,370 (3,930 ) 31/03/2011
49,591 (6,751 )
Total
8,560
(note 22)
During 2009 the Company contracted two unquoted futures contracts, the notional underlying of which consists of the Company’s shares, with a solvent financial institution. The two contracts have shares 2 million and 2.2 million underlying with an exercise price of Euros 11.6107 and Euros 11.9864, respectively. The contracts were to expire on 30 December 2010, although the Company could terminate them prior to this date. On 30 December 2010 it was agreed to extend the futures contract to 31 March 2011, through a novation without liquidation under the same terms and conditions. The contracts are settled by differences between the market value of the notional underlying and the exercise price.
b) Bond issue hedging derivative financial instruments
See explanation in note 17 (f).

104

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Credit risk
Exposure to credit risk
The carrying amount of financial assets represents the maximum exposure to credit risk. At 31 December 2010 and 2009 the maximum level of exposure to credit risk is as follows:
Thousands of Euros
Carrying amount Note 31/12/10 31/12/09
Non-current financial assets
11 7,535 3,731
Other current financial assets
14 12,946 6,547
Financial derivatives
14 — 1,670
Trade receivables
13 224,355 207,840
Other receivables
13 35,142 31,364
Cash and cash equivalents
16 239,649 249,372
519,627 500,524
The maximum level of exposure to risk associated with receivables at 31 December 2010 and 2009, by geographical area, is as follows.
Thousands of Euros
Carrying amount 31/12/10 31/12/09
Domestic
70,517 70,521
EU countries
46,787 47,755
United States of America
43,833 29,130
United Kingdom
3,423 3,054
Other European countries
3,162 5,454
Other regions
56,633 51,926
224,355 207,840

105

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Impairment losses
Details of the maturity of trade receivables, net of impairment provisions are as follows:
Thousands of Euros
31/12/10 31/12/09
Not due
148,838 120,339
Overdue less than 1 month
21,860 38,278
Overdue from 1 to 4 months
32,729 25,597
Overdue from 4 months to 1 year
14,812 17,357
Overdue more than a year
6,116 6,269
224,355 207,840
Unimpaired overdue receivables mainly relate to public entities.
Movement in the provision for bad debts was as follows:
Thousands of Euros
31/12/10 31/12/09 31/12/08
Opening balance
4,038 3,172 3,285
Net provisions for the year
357 712 317
Net cancellations for the year
(796 ) (42 ) (249 )
Translation differences
178 196 (181 )
Closing balance
3,777 4,038 3,172
An analysis of the concentration of credit risk is provided in note 5.

106

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Liquidity risk
Details of the contracted maturity date of financial liabilities, including borrowing costs and excluding the effects of offsetting agreements, are as follows:
Thousands of Euros
Carrying More
amount at Contractual 6 months 6 - 12 1-2 2- 5 than 5
Carrying amount
Note 31/12/09 flows or less months years years years
Non-derivative financial liabilities
Bank loans
22 382,566 412,390 88,707 15,087 83,772 177,413 47,411
Other financial liabilities
22 21,449 27,420 6,927 2,582 4,417 10,076 3,418
Bonds and other securities
22 423,675 687,798 27,440 14,317 28,634 85,903 531,504
Finance lease liabilities
22 10,936 11,334 230 4,751 3,294 2,586 473
Suppliers
23 120,909 120,909 120,550 359 — — —
Other current liabilities
24 1,754 1,754 1,754 — — — —
Derivative financial liabilities
Interest rate swap
22 3,333 3,333 — — — 3,333 —
Unquoted futures
14 (1,670 ) (1,670 ) — (1,670 ) — — —
Total
962,952 1,263,268 245,608 35,426 120,117 279,311 582,806

107

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Thousands of Euros
Carrying More
amount at Contractual 6 months or 6 - 12 1-2 2- 5 than 5
Carrying amount
Note 31/12/10 flows less months years years years
Non-derivative financial liabilities
Bank loans
22 392,361 420,168 117,256 66,428 87,986 92,561 55,937
Other financial liabilities
22 20,150 22,361 8,150 2,134 3,467 6,283 2,327
Bonds and other securities
22 456,645 728,893 23,771 15,537 31,073 93,220 565,292
Finance lease liabilities
22 8,014 8,629 2,034 1,505 2,412 2,348 330
Debts with associates
33 1,162 1,162 1,162 — — — —
Suppliers
23 160,678 160,678 160,657 21 — — —
Other current liabilities
24 2,629 2,629 2,629 — — — —
Derivative financial liabilities
Interest rate swap
22 1,809 1,809 — — — 1,809 —
Unquoted futures
22 6,751 6,751 6,751 — — — —
Total
1,050,199 1,353,080 322,410 85,625 124,938 196,221 623,886

108

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Currency risk
The Group’s exposure to currency risk is as follows:
Thousands of Euros
31/12/09
EUR (*) USD (**)
Trade receivables
1,839 7,308
Loans to Group companies
16,854 —
Trade payables
(252 ) (2,339 )
Payables to Group companies
(10,365 ) (17,946 )
Loans with Group companies
— (10,431 )
Non-current bank loans
(6,854 ) —
Non-current bonds
(10,000 ) —
Balance sheet exposure
(8,778 ) (23,408 )
(*) balances in Euros in subsidiaries with USD local currency
(**) Balances in USD in subsidiaries with Euro local currency
Thousands of Euros
31/12/10
EUR (*) USD (**)
Trade receivables
67 3,938
Receivables from Group companies
12 —
Loans to Group companies
16,852 —
Cash
415 45
Trade payables
(533 ) (6,200 )
Payables for Group companies
(6,828 ) (21,455 )
Current bank loans
(5,875 ) —
Non-current bank loans
(979 ) (262 )
Non-current bonds
(9,860 ) —
Balance sheet exposure
(6,729 ) (23,934 )
(*) balances in Euros in subsidiaries with USD local currency
(**) Balances in USD in subsidiaries with Euro local currency

109

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
The most significant exchange rates applied during the years ended 31 December 2010 and 2009 are as follows:
Average exchange rate Closing exchange rate
Euro 2010 2009 31/12/10 31/12/09
USD
1.34 1.38 1.34 1.44
A sensitivity analysis for foreign exchange fluctuations is as follows:
Had the US Dollar strengthened by 10% against the Euro at 31 December 2010, equity would have increased by Euros 34,973 thousand (Euros 35,795 thousand at 31 December 2009) and profit would have decreased by Euros 3,066 thousand (at 31 December 2009 it would have decreased by Euros 1,626 thousand). This analysis assumes that all other variables are held constant, especially that interest rates remain constant. This analysis has been performed using the same criteria as in 2009.
A 10% weakening of the US Dollar against the Euro at 31 December 2010 and 2009 would have had the opposite effect for the amounts shown above, all other variables being held constant.
Interest-rate risk
Interest-rate profile
To date, the profile of interest on interest-bearing financial instruments is as follows:
Thousands of Euros
31/12/10 31/12/09
Fixed-interest financial instruments
Financial assets
19,220 9,674
Financial liabilities
(457,521 ) (423,675 )
(438,301 ) (414,001 )
Variable-interest financial instruments Financial liabilities
(399,499 ) (393,502 )
(399,499 ) (393,502 )
(837,800 ) (807,503 )

110

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Sensitivity analysis
A 100 basis point variation in interest rates at the presentation date of 31 December 2010 would have increased / decreased equity and consolidated profit after income tax by Euros 3,794 thousand. This analysis assumes that all other variables are held constant, especially that exchange rates remain constant.
A 100 basis point variation in interest rates at the presentation date of 31 December 2009 would have increased / decreased equity and consolidated profit after income tax by Euros 4,732 thousand.
(33) Balances and Transactions with Related Parties
Details of balances with related parties are as follows:
Thousands of Euros
31/12/10 31/12/09
Receivables from associates
5 812
Debts with associates
(1,162 ) —
Payables to associates
— (22 )
Payables to members of the board of directors
(62 ) (121 )
Payables to other related parties
(4,641 ) (3,322 )
(5,860 ) (2,653 )
Payables are included in suppliers and trade payables (see note 23).
Transactions with related parties
Transactions with related parties have been performed as part of the group’s ordinary trade and have been performed at arm’s length.
Group transactions with related parties during 2008 were as follows:
Thousands of Euros
Key
management Other related Board of directors
Associates personnel parties of the Company
Net purchases
125 — — —
Other service expenses
— — 4,981 180
Personnel expenses
— 4.253 — 1,995
125 4,253 4,981 2,175

111

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
Dividends received by the Board of directors of the Company amounted to Euros 2,600 thousand in 2008.
Group transactions with related parties during 2009 were as follows:
Thousands of Euros
Key
management Other related Board of directors
Associates personnel parties of the Company
Net purchases
86 — — —
Net sales
(700 ) — — —
Other service expenses
— — 7,257 240
Personnel expenses
— 5,849 — 2,148
(614 ) 5,849 7,257 2,388
Dividends received by the Board of directors of the Company amounted to Euros 6,152 thousand in 2009.
Group transactions with related parties during 2010 are as follows:
Thousands of Euros
Key
management Other related Board of directors
Associates personnel parties of the Company
Net purchases
505 — — —
Net sales
(14 ) — — —
Other service expenses
— — 12,506 180
Personnel expenses
— 5,839 — 2,066
491 5,839 12,506 2,246
Dividends received by the Board of directors of the Company amounted to Euros 2,062 thousand in 2010.
“Other service expenses” include costs for professional services with related companies amounting to Euros 7,590 thousand. These costs correspond to those incurred related to the share capital increase and the issuance of debt which is expected to be carried out relating to the acquisition of Talecris (see note 15).
Non-employee board member representing shareholders interests have received no remuneration during 2010, 2009 or 2008.

112

GRIFOLS, S.A. AND SUBSIDIARIES
Notes to the Consolidated Financial Statements
The Group has not extended any advances or loans to the members of the board of directors or key management personnel nor has it assumed any guarantee commitments on their behalf. It has also not assumed any pension or life insurance obligations on behalf of former or current members of the board of directors or key management personnel.
(34) Subsequent Events
On 13 January 2011, the Group closed its scheduled issue of High Yield Senior Unsecured Notes for an amount of US Dollars 1,100 million, with a 7 year maturity period and an annual coupon of 8.25%. This issue, together with the already completed syndicated loan for an amount of US Dollars 3,400 million, enabled the Company to obtain US Dollars 4,500 million, the estimated maximum financing requirement for the acquisition of Talecris.
At the extraordinary general shareholders’ meeting held on 25 January 2011, the Company agreed to increase share capital through the issue of 87 million new non-voting shares, which it will use in its acquisition of Talecris. These shares are scheduled to be listed on the NASDAQ Global Market (United States) and the Automated Quotation System (“mercado continuo”) (Spain).
The Group has therefore completed all the tranches of the proposed financing structure to conclude the transaction, which is still pending approval by the U.S. Federal Trade Commission (FTC).
On 5 March 2011 Grifols has extended the deadline for closing the acquisition of Talecris Biotherapeutics Holdings Corp. and the financing and commitments with those extending the financing to 30 June 2011.
The Board of Directors of Grifols, S.A. approved these Consolidated Financial Statements on 29 March 2011.

113

APPENDIX I
GRIFOLS,S.A. AND SUBSIDIARIES
OPERATING SEGMENTS
(expressed in thousands of Euros)
Bioscience Hospital Diagnostics Raw materials Others/Unallocated Consolidated
2010 2009 2008 2010 2009 2008 2010 2009 2008 2010 2009 2008 2010 2009 2008 2010 2009 2008
Revenues
773,372 694,969 617,918 89,552 86,328 82,566 109,088 103,091 85,705 4,815 22,665 22,794 13,903 6,133 5,328 990,730 913,186 814,311
Total revenues
773,372 694,969 617,918 89,552 86,328 82,566 109,088 103,091 85,705 4,815 22,665 22,794 13,903 6,133 5,328 990,730 913,186 814,311
Profit/(Loss) for the segment
306,091 297,584 262,229 7,401 8,374 8,534 6,793 12,136 13,603 2,110 3,850 7,369 7,785 6,133 5,328 330,180 328,077 297,063
Unallocated expense
(120,497 ) (101,549 ) (94,102 ) (120,497 ) (101,549 ) (94,102 )
Operating profit
209,683 226,528 202,961
Finance income/expenses
(51,020 ) (22,585 ) (30,716 )
Share of profit/(loss) of equity accounted investees
(879 ) 0 0 0 0 0 0 51 24 0 0 0 0 0 0 (879 ) 51 24
Income tax expense
(42,517 ) (56,424 ) (50,153 )
Profit for the year after tax
115,267 147,570 122,116
Segment assets
1,062,464 994,245 798,843 85,992 68,214 63,660 129,824 82,202 67,087 954 1,312 4,379 0 0 0 1,279,234 1,145,973 933,969
Equity accounted investments
516 0 0 0 0 0 0 383 374 0 0 0 0 0 0 516 383 374
Unallocated assets
609,232 510,821 245,896 609,232 510,821 245,896
Total assets
1,888,982 1,657,177 1,180,239
Segment liabilities
74,489 79,988 75,120 14,486 12,579 11,909 12,573 10,763 9,066 0 0 0 0 0 0 101,548 103,330 96,095
Unallocated liabilities
1,080,044 975,319 602,865 1,080,044 975,319 602,865
Total liabilities
1,181,592 1,078,649 698,960
Other information:
Amortisation and depreciation
21,630 21,893 21,644 4,719 3,808 3,725 8,265 5,261 5,000 0 0 67 11,162 8,592 2,820 45,776 39,554 33,256
Expenses that do not require cash payments
(526 ) (2,059 ) (1,744 ) (12 ) (70 ) 32 0 (1 ) 15 0 0 (7 ) 0 (26 ) (275 ) (538 ) (2,156 ) (1,979 )
Additions for the year of property, plant & equipment and intangible assets
65,344 70,702 65,954 13,132 7,524 9,266 15,897 14,067 14,078 0 0 516 11,424 26,477 39,879 105,797 118,770 129,693
This Appendix forms an integral part of note 6 to the consolidated financial statements

1 of 2

APPENDIX I
GRIFOLS, S.A. AND SUBSIDIARIES
GEOGRAPHICAL INFORMATION
(expressed in thousands of Euros)
Spain European Union United States Rest of the world Consolidated
2010 2009 2008 2010 2009 2008 2010 2009 2008 2010 2009 2008 2010 2009 2008
Revenues
227,947 225,759 190,809 204,244 198,832 213,290 339,018 296,659 290,666 219,521 191,936 119,546 990,730 913,186 814,311
Assets by geographic areas
682,473 632,537 532,392 117,706 82,245 96,845 936,030 821,641 502,797 152,773 120,754 48,205 1,888,982 1,657,177 1,180,239
Other information:
Additions for the year of property, plant & equipment and intangible assets
50,319 65,046 93,005 3,972 2,341 999 43,847 43,726 33,475 7,659 7,657 2,214 105,797 118,770 129,693
This Appendix forms an integral part of note 6 to the consolidated financial statements

2 of 2

APPENDIX II
GRIFOLS, S.A. AND SUBSIDIARIES
Changes in Other Intangible Assets
for the year ended
31 December 2010
(Expressed in thousands of Euros)
Balances at Translation Balances at
31/12/2009 Additions Transfers Disposals differences 31/12/2010
Development costs
55,414 6,614 0 (26 ) 69 62,071
Concessions, patents, licenses brands & similar
46,259 2,410 847 0 3,227 52,743
Software
28,597 5,455 318 (20 ) 352 34,702
Other intangible assets
513 2,121 0 (299 ) 10 2,345
Total cost of intangible assets
130,783 16,600 1,165 (345 ) 3,658 151,861
Accum. amort. of development costs
(29,427 ) (3,699 ) 0 0 (69 ) (33,195 )
Accum. amort of concessions, patents, licenses, brands & similar
(15,526 ) (1,603 ) (845 ) 0 (654 ) (18,628 )
Accum. amort. of software
(16,430 ) (4,965 ) 1 20 (172 ) (21,546 )
Accum. amort. of other intangible assets
0 (189 ) (4 ) 0 0 (193 )
Total accum. amort intangible assets
(61,383 ) (10,456 ) (848 ) 20 (895 ) (73,562 )
Impairment of other intangible assets
(15 ) 0 0 15 0 0
Carrying amount of intangible assets
69,385 6,144 317 (310 ) 2,763 78,299
This appendix forms an integral part of note 8 to the consolidated financial statements

1 of 3

APPENDIX II
GRIFOLS, S.A. AND SUBSIDIARIES
Changes in Other Intangible Assets
for the year ended
31 December 2009
(Expressed in thousands of Euros)
Balances at Business Translation Balances at
31/12/2008 Additions combinations Transfers Disposals differences 31/12/2009
Development costs
47,299 8,146 0 0 0 (31 ) 55,414
Concessions, patents, licenses brands & similar
40,461 1 6,525 (5 ) 0 (723 ) 46,259
Software
22,272 6,700 0 1 (240 ) (136 ) 28,597
Other intangible assets
0 508 0 5 0 0 513
Total cost of intangible assets
110,032 15,355 6,525 1 (240 ) (890 ) 130,783
Accum. amort. of development costs
(23,878 ) (5,580 ) 0 0 0 31 (29,427 )
Accum. amort of concessions, patents, licenses, brands & similar
(14,881 ) (806 ) 0 0 0 161 (15,526 )
Accum. amort. of software
(13,517 ) (3,097 ) 0 0 132 52 (16,430 )
Total accum. amort intangible assets
(52,276 ) (9,483 ) 0 0 132 244 (61,383 )
Impairment of other intangible assets
0 (15 ) 0 0 0 0 (15 )
Carrying amount of intangible assets
57,756 5,857 6,525 1 (108 ) (646 ) 69,385
(note 3 )
This appendix forms an integral part of note 8 to the consolidated financial statements

2 of 3

APPENDIX II
GRIFOLS, S.A. AND SUBSIDIARIES
Changes in Other Intangible Assets
for the year ended
31 December 2008
(Expressed in thousands of Euros)
Balances at Translation Balances at
31/12/2007 Additions Transfers Disposals differences 31/12/2008
Intangible assets
Development costs
43,141 5,255 0 (1,146 ) 49 47,299
Concessions, patents, licenses brands and similar
40,790 0 0 (1,618 ) 1,289 40,461
Software
17,704 4,489 (59 ) (8 ) 146 22,272
Total cost of intangible assets
101,635 9,744 (59 ) (2,772 ) 1,484 110,032
Accum. amort. of development costs
(18,916 ) (4,634 ) (287 ) 0 (41 ) (23,878 )
Accum. amort of concessions, patents, licenses, brands & similar
(14,110 ) (2,322 ) 287 1,616 (352 ) (14,881 )
Accum. amort. of software
(11,386 ) (2,124 ) 59 10 (76 ) (13,517 )
Total Accum. amort intangible assets
(44,412 ) (9,080 ) 59 1,626 (469 ) (52,276 )
Carrying amount of intangible assets
57,223 664 0 (1,146 ) 1,015 57,756
This appendix forms an integral part of note 8 to the consolidated financial statements

3 of 3

APPENDIX III
GRIFOLS, S.A. AND SUBSIDIARIES
Changes in Property, Plant and Equipment
for the year ended
31 December 2010
(Expressed in thousands of Euros)
Balances at Translation Balances at
31/12/09 Additions Transfers Disposals differences 31/12/10
Cost:
Land and buildings
142,600 10,594 28,930 (1,085 ) 3,703 184,742
Plant and machinery
344,030 35,356 21,857 (8,242 ) 12,268 405,269
Under construction
70,781 43,247 (49,694 ) 0 1,950 66,284
557,411 89,197 1,093 (9,327 ) 17,921 656,295
Accumulated depreciation:
Buildings
(9,502 ) (1,890 ) (16 ) 0 (139 ) (11,547 )
Plant and machinery
(176,204 ) (33,430 ) (1,394 ) 6,016 (4,956 ) (209,968 )
(185,706 ) (35,320 ) (1,410 ) 6,016 (5,095 ) (221,515 )
Impairment of other property, plant and equipment
0 (649 ) 0 0 0 (649 )
Carrying amount
371,705 53,228 (317 ) (3,311 ) 12,826 434,131
This appendix forms an integral part of note 9 to the consolidated financial statements

1 of 3

APPENDIX III
GRIFOLS, S.A. AND SUBSIDIARIES
Changes in Property, Plant and Equipment
for the year ended
31 December 2009
(Expressed in thousands of Euros)
Balances at Business Translation Balances at
31/12/08 Additions combinations Transfers Disposals differences 31/12/09
Cost:
Land and buildings
111,067 9,729 0 22,905 0 (1,101 ) 142,600
Plant and machinery
287,761 33,994 2,307 27,784 (5,881 ) (1,935 ) 344,030
Under construction
63,620 59,692 0 (50,882 ) (757 ) (892 ) 70,781
462,448 103,415 2,307 (193 ) (6,638 ) (3,928 ) 557,411
Accumulated depreciation:
Buildings
(8,049 ) (1,514 ) 0 0 0 61 (9,502 )
Plant and machinery
(153,390 ) (28,557 ) 0 192 4,942 609 (176,204 )
(161,439 ) (30,071 ) 0 192 4,942 670 (185,706 )
Carrying amount
301,009 73,344 2,307 (1 ) (1,696 ) (3,258 ) 371,705
(note 3)
This appendix forms an integral part of note 9 to the consolidated financial statements

2 of 3

APPENDIX III
GRIFOLS, S.A. AND SUBSIDIARIES
Changes in Property, Plant and Equipment
for the year ended
31 December 2008
(Expressed in thousands of Euros)
Balances at Business Translation Balances at
31/12/07 Additions combinations Transfers Disposals differences 31/12/08
Cost:
Land and buildings
79,845 29,142 0 641 0 1,439 111,067
Plant and machinery
233,812 35,408 3 22,423 (5,939 ) 2,054 287,761
Under construction
30,079 55,399 0 (23,948 ) (128 ) 2,218 63,620
343,736 119,949 3 (884 ) (6,067 ) 5,711 462,448
Accumulated depreciation:
Buildings
(6,735 ) (1,234 ) 0 (39 ) 29 (70 ) (8,049 )
Plant and machinery
(135,669 ) (22,942 ) 0 923 5,027 (729 ) (153,390 )
(142,404 ) (24,176 ) 0 884 5,056 (799 ) (161,439 )
Carrying amount
201,332 95,773 3 0 (1,011 ) 4,912 301,009
(note 3 )
This appendix forms an integral part of note 9 to the consolidated financial statements

3 of 3

APPENDIX IV
GRIFOLS, S.A. AND SUBSIDIARIES
Non-current Loans and Borrowings
for the year ended
31 December 2010
(Expressed in thousands of Euros)
Thousands of Euros
Initial loan
Concession arrangement
Loan Currency Interest rate date Maturity date Face amount expenses Carrying amount
Syndicated loan — Club deal
EUR Euribor + 0,8% 01/05/2008 26/05/2013 350,000 (2,427 ) 99,408
Instituto de crédito Oficial
EUR Euribor + 1% 01/06/2006 26/05/2016 30,000 (210 ) 17,955
Caixa Catalunya — Mortgage loan
EUR Euribor + 0,9% 01/02/2008 01/02/2018 14,000 (294 ) 10,115
Banco Santander
EUR ICO + 1,8% 01/06/2009 01/06/2016 6,000 — 5,400
Caja de Madrid
EUR Euribor + 1% 05/06/2009 05/06/2016 6,000 — 5,400
Banco Guipuzcoano
EUR Euribor + 1% 25/03/2010 25/03/2020 8,500 — 8,500
Banco Sabadell
EUR Euribor + 1% 11/06/2010 30/06/2012 1,465 — 1,413
SCH
EUR 1.75 % 13/10/2010 13/10/2017 900 — 876
Ibercaja
EUR Euribor + 1,99% 30/07/2009 31/07/2016 1,800 — 1,664
Caja de Madrid
Euribor + 2% 09/03/2010 25/03/2020 10,000 — 10,000
SCH
Euribor + 1% 18/11/2010 31/01/2012 169 — 169
BBVA — Mortgage loan
EUR Euribor + 1,2% 21/10/2008 31/12/2024 45,000 (676 ) 39,201
Caixa Catalunya
EUR ICO + 1,99% 30/07/2009 25/08/2016 1,440 — 1,353
Caixa Galicia
EUR Euribor + 1% 11/06/2010 25/06/2020 1,180 — 1,003
Banca Toscana
EUR 6 months Euribor + 1% 08/05/2008 30/06/2013 3,000 — 939
Cofides
EUR 6 months Euribor + 0,45% 01/08/2008 20/08/2017 6,854 — 5,875
Cofides
EUR Euribor + 2% 20/09/2011 20/03/2017 10,745 — 10,177
497,053 (3,607 ) 219,448
Non-current finance lease creditors (see note 22) — — 4,734
497,053 (3,607 ) 224,182
This appendix forms an integral part of note 22 to the consolidated financial statements.

1 of 3

APPENDIX IV
GRIFOLS, S.A. AND SUBSIDIARIES
Non-current Loans and Borrowings
for the year ended
31 December 2009
(Expressed in thousands of Euros)
Thousands of Euros
Initial loan
Concession arrangement
Loan Currency Interest rate date Maturity date Face amount expenses Carrying amount
Syndicated loan —Club deal
EUR Euribor + 0,8% 01/05/2008 26/05/2013 350,000 (2,427 ) 195,471
Instituto de crédito Oficial
EUR Euribor + 1% 01/06/2006 26/05/2016 30,000 (210 ) 21,933
Caixa Catalunya — Mortgage loan
EUR Euribor + 0,9% 01/02/2008 01/02/2018 14,000 (294 ) 11,733
Banco Santander
EUR ICO + 1,8% 01/06/2009 01/06/2016 6,000 — 6,000
Caja de Madrid
EUR Euribor + 1% 05/06/2009 05/06/2016 6,000 — 6,000
Ibercaja
EUR Euribor + 1,9% 30/07/2009 31/07/2016 1,800 — 1,800
BBVA — Mortgage loan
EUR Euribor + 1,2% 21/10/2008 31/12/2024 45,000 (676 ) 33,649
Caixa Catalunya
EUR ICO + 1,99% 30/07/2009 25/08/2016 1,440 — 1,440
Banca Toscana
EUR 6 months Euribor + 1% 08/05/2008 30/06/2013 3,000 — 1,552
Cofides
EUR 6 months Euribor + 0,45% 01/08/2008 20/08/2017 6,854 — 6,854
464,094 (3,607 ) 286,432
Non-current finance lease creditors (see note 22) — — 6,202
464,094 (3,607 ) 292,634
This appendix forms an integral part of note 22 to the consolidated financial statements.

2 of 3

APPENDIX IV
GRIFOLS, S.A. AND SUBSIDIARIES
Non-current Loans and Borrowings
for the year ended
31 December 2008
(Expressed in thousands of Euros)
Thousands of Euros
Initial loan
arrangement
Loan Currency Interest rate Concession date Maturity date Face amount expenses Carrying amount
Syndicated loan —Club deal
EUR / USD Euribor + 0,8% 01/05/2008 26/05/2013 350,000 (1,984 ) 225,320
Institut Catalá de Finances
EUR 5.70 % 27/01/2005 28/02/2010 6,247 (62 ) 312
Instituto de Crédito Oficial
EUR 4.94 % 01/06/2006 26/05/2016 30,000 (210 ) 25,907
Caixa Catalunya — Mortgage loan
EUR 5.25 % 01/02/2008 01/02/2018 14,000 (294 ) 13,350
BBVA — Mortgage loan
EUR 6.50 % 21/10/2008 31/12/2024 45,000 (676 ) 30,463
Banca Toscana
EUR 5.33 % 08/05/2008 30/06/2013 3,000 — 2,183
Cofides
EUR 5.61 % 01/08/2008 20/08/2017 6,854 — 6,854
448,247 (3,226 ) 304,389
Non-current finance lease creditors (see note 22) — — 7,124
448,247 (3,226 ) 311,513
This appendix forms an integral part of note 22 to the consolidated financial statements.

3 of 3

TABLE OF CONTENTS